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Individuals born with primary immune deficiency diseases (PIDD) have a dysfunctional 
immune system, and many are treated by lifelong injections of immunoglobulin therapy.  
Studies have shown that these patients have low health-related quality of life (HRQOL) 
and well-being (WB) and that these outcomes might be improved by the availability of 
therapy innovated according to preferences for fewer needle sticks or a shorter infusion 
time.  Regulators at the U.S. Food and Drug Administration (FDA) have approved 
therapies innovated per these preferences.  However, there is limited data demonstrating 
how these innovations impact HRQOL and WB.  Using the biopsychosocial model, the 
purpose of this cross sectional quantitative study was to evaluate whether patients with 
PIDD using therapies innovated for fewer needle sticks or a shorter infusion time had a 
higher mean HRQOL and WB compared to those who were not.  The study included 153 
patients who completed the Patient Reported Outcomes Measurement Information 
System (PROMIS)-29 survey.  The dependent variables were HRQOL and WB measured 
by PROMIS-29, and the independent variables were the medical product innovations. 
Independent samples t tests results showed mean PROMIS-29 scores were not 
statistically different (p > .05).  This suggests patients were optimized according to their 
treatment preference.  A subgroup of patients who had taken the PROMIS-29 survey 
more than once concurrent with switching to a therapy aligned with patient preferences 
showed improved HRQOL and WB.  These findings have implications for positive social 
change in that seeking the patient’s voice to inform medical product innovation and FDA 
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Chapter 1: Introduction to the Study 
Introduction 
Primary immune deficiency disease (PIDD) comprises a group of more than 230 
different rare genetic disorders where immune system cells, antibodies, and complement 
proteins are missing, defective, or present in insufficient amounts (Chapel et al., 2014).  
Persons with an immune system deficiency have greater susceptibility to common and 
unusual infections which are chronic, more severe, of longer duration, and are more 
difficult to treat with standard medical care, compared to individuals with an intact 
immune system (Chapel et al., 2014; Costa-Carvalho et al., 2014; Heath, Lehman, 
Saunders, & Craig, 2016).  Examples of the effects of immune system deficiency include 
bone, gastrointestinal, mucous membrane, and respiratory infections; abscesses of the 
brain, liver, or lungs; autoimmune diseases (due to an improperly functioning immune 
system) leading to anemia, arthritis, or asthma; abnormal gland development; heart 
defects; and increased cancer risk (American Academy of Asthma, Allergy, and 
Immunology, 2016; Costa-Carvalho et al., 2014). 
In the United States, researchers estimate prevalence of PIDD to be 1 in 2000 
children, 1 in 1200 individuals, and 1 in 600 households (Jiang, Torgerson, & Ayars, 
2015; Melamed, Testori, & Spirer, 2012).  The rarity of PIDD raises public health 
concerns and merits study because delayed diagnosis often results in life-threatening 
illnesses and in high costs from greater use of health care services, such as emergency 
room visits and hospital admittance prior to the individual receiving effective treatment 
(Chapel et al., 2014; Resnick, Bhatt, Sidi, & Cunningham-Rundles, 2013).  Haddad, 
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Barnes, and Kafal (2012) cited survey results that revealed an average 9-year delay from 
presentation of symptoms to diagnosis.  Haddad et al. also commented on low PIDD 
awareness in the medical community as a possible cause for the delay in diagnosis.  
Menzin, Sussman, Munsell, and Zbrozek (2014) determined the mean PIDD infection-
related medical costs, over a seven month period in 2010, to be U.S. $11,925 per patient.  
The overall mean cost per patient included the following individual patient costs: an 
emergency visit ($899), an outpatient visit ($1,460), and an inpatient hospital visit 
($38,574; Menzin et al., 2014).  Jiang, Torgerson, and Ayars (2015) found a 1.7% 
increased risk of death with each year of delayed diagnosis, and a 4.5% increased risk of 
death with each increase in chronological age at diagnosis.   
Although there is no treatment for PIDD that can repair the immune system to 
normal function, lifelong (after diagnosis) immunoglobulin antibody replacement therapy 
is an option for many patients.  Medical product manufacturers have developed 
immunoglobulin replacement therapies for PIDD treatment and have made these 
therapies available to patients through their medical practitioners, subsequent to approval 
by the Food and Drug Administration (FDA; FDA, 2015b).  Thus, medical practitioners 
are prescribing lifelong regular infusions of immunoglobulins (also referred to as immune 
globulins or antibodies) for PIDD treatment (Menzin, Sussman, Munsell, & Zbrozek, 
2014).  Moreover, medical product manufacturers have conducted clinical trials 
demonstrating the safety and efficacy of immunoglobulin replacement therapy based on 
biomedical endpoints such as blood levels of immunoglobulin (Melamed et al., 2012).  
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The FDA has subsequently approved a number of these medical products for 
immunoglobulin replacement therapy (Schroeder & Dougherty, 2012). 
Though immunoglobulin replacement therapies are available, the biomedical and 
the psychosocial burdens that patients face daily, and for an extended duration of time 
with chronic diseases such as PIDD, are a serious global public health concern (Heath et 
al., 2016; Hirsch, Walker, Chang, & Lyness, 2012).  Examples of some of the burdens 
that patients with PIDD face include decreased health-related quality of life (HRQOL) 
due to anxiety and depression around fear of infection, missed days of school or work, 
inability to work; and feelings of isolation due to the inability to function socially with 
friends and family and as a member of society (Bienvenu et al., 2016).  Menzin et al. 
(2014) cited a Jeffrey Modell Centers Network survey which showed that the average 
patient with PIDD has 70 emergency room visits, 19 hospitalizations, and 34 missed days 
of school or work in the year preceding diagnosis.  These numbers underscore the public 
health issue for patients with PIDD.   
Although immunoglobulin replacement therapy (IGRT) mitigates some of the 
biomedical and psychosocial burdens of PIDD caused by recurrent infections (Melamed 
et al., 2012), the life-long therapy regimen creates other biomedical and psychosocial 
burdens.  Examples of life-long therapy burdens include systemic and localized reactions 
to therapy; travel to an infusion clinic and wait time at the clinic; and frequency, duration, 
and route of therapy administration (Dashti-Khavidaki et al., 2009; Haddad, Barnes, & 
Kafal, 2012).  Because immunoglobulin replacement therapy is administered 
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intravascularly, needles are involved; thus, needle sticks are also a burden (Espanol, 
Prevot, Drabwell, Sondhi, & Olding, 2014).   
To address these issues, researchers, medical products manufacturers, and the 
FDA are currently seeking more patient input regarding treatment preferences and 
treatment psychosocial outcomes, such as HRQOL and well-being.  Patient treatment 
preferences have informed innovations in therapies developed by medical product 
manufacturers, which are now FDA-approved and commercially available.  Examples of 
innovative therapies include treatments which enable patients to self-administer 
medication in their home instead of intravenous infusions administered in a clinical 
setting by a medical practitioner (Jiang et al., 2015). Additionally, in 2014 the FDA 
approved a therapy that patients can self-administer with fewer needle sticks and in a 
shorter time per infusion (Espanol et al., 2014; Garduff & Nicoloay, 2006; Ponsford et 
al., 2015; Wasserman, 2014).   
Individuals researching treatment regimens indicated for patients with PIDD 
might also elect to use validated survey instruments as a tool for assessing patient 
psychosocial outcomes (such as HRQOL and well-being).  Researchers have studied 
HRQOL and well-being in patients with PIDD focusing on location of therapy 
administration, route of administration, and patient preferences related to therapy 
frequency, duration, and number of needle sticks, using standard validated survey 
instruments such as the EuroQOL five-dimension questionnaire (EQ-5D) and the Short 
Form Health Survey (SF-36; Espanol et al., 2014; Jiang et al., 2015; Tabolli et al., 2014; 
Vultaggio et al., 2015).  Researchers with the National Institutes of Health (NIH) 
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developed the Patient-Reported Outcomes Measurement Information System (PROMIS) 
survey instruments to gather HRQOL and well-being information and to measure health 
outcomes from the patient’s perspective about chronic diseases globally (NIH, 2017).  In 
addition, the Immune Deficiency Foundation (IDF), an advocacy organization for 
patients with PIDD, is partnering with the NIH to administer the abbreviated PROMIS 
(called PROMIS-29) survey instrument to individuals from IDF’s patient registry (C. 
Scalchunes, personal communication, October 20, 2016).  In this study I present the first 
findings of HRQOL and well-being of patients with PIDD as measured by the PROMIS-
29 survey instrument.         
The goal of this study was to evaluate whether medical product innovations based 
on patient treatment preferences for number of needle sticks and infusion time improve 
HRQOL and well-being, as measured by the PROMIS-29 instrument.  The implications 
of this study for positive social change include providing additional evidence supporting 
the gathering and use of patient preferences in medical product development and 
regulatory decision-making.  Findings may encourage researchers, manufacturers, and 
regulators to shift from a purely biomedical (or clinical) focus to a psychosocial (or 
public health) one whereby they consider the psychosocial impact of therapy innovation. 
Incorporating this type of focus and considering patient preferences for treatment may 
result in improved HRQOL and well-being for patients with PIDD.   
Background 
Patients have access to medical products because there exists a supply chain from 
medical product manufacturers, though regulatory authority (i.e. FDA) review and 
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approval, to recognition of the medical product by insurance companies and distribution 
to pharmacies, and culminating with a physician’s prescription (FDA, 2015b).  
Researchers, manufacturers, regulatory authorities, and medical practitioners seek patient 
feedback (or patient-reported outcomes) according to their role within the medical 
products supply chain.  For instance, medical product manufacturers might want to 
understand treatment satisfaction and patient preferences for treatment as they innovate 
medical products designed to reduce the burden chronic disease poses to the patient on a 
daily basis; regulatory authorities might be interested in HRQOL reports to establish a 
risk to benefit profile as they review a medical product application; and medical 
practitioners might seek to evaluate patient reports of health status and adherence to 
regimen as they talk with the patient regarding an optimal treatment plan (Willke, Burke, 
& Erickson, 2004).  Willke, Burke, and Erickson (2004) reviewed drug medical product 
labeling between the years 1997-2002 to determine the extent to which patient-reported 
outcomes were used for medical product manufacturers’ drug innovation and for 
regulatory review and approval by FDA.  Willke et al. (2004) found patient-reported 
outcomes were reported in 30% (64 of 215) of the labels reviewed, behind clinical 
endpoints (62%) and laboratory endpoints (50%).  According to their review, the medical 
products innovated and approved using patient-reported outcomes were used to treat 
inflammation, conjunctivitis; and disorders of the central nervous, gastrointestinal, 
respiratory, eye, and urologic systems (Willke et al., 2004). 
The theoretical framework for this dissertation stems from the concept that 
medical products are innovated not only to alleviate the clinical presentation of disease, 
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but also to help patients manage their lives while also managing a disease state which 
cannot be cured.  In this study, I focused on two aspects of PIDD management which the 
literature suggested patients expressed a desire to improve: (a) reduction in the number of 
needle sticks and (b) shorter infusion time, but where there is currently limited data 
showing whether these medical product innovations result in better outcomes in terms of 
HRQOL and well-being; hence there is a gap in knowledge. 
Biomedical evidence that a medical product works and has benefits to the patient 
which outweigh the risks is demonstrated through clinical trials.  The literature is replete 
with studies showing that immunoglobulin replacement therapy boosts the immune 
system of patients with PIDD.  The goal of this study, and the reason why the study was 
needed, was to bring medical product innovation into the public health discipline by 
seeking to generate evidence that a medical product works and also has benefits of 
improved patient HRQOL and well-being because psychosocial parameters of patient 
preference for treatment were considered by medical product manufacturers in their 
development of the medical product. 
To make this dissertation more relatable to the reader who is less familiar with 
rare diseases such as PIDD, I used this section to make an analogy of PIDD (a rare 
disease) to Type 2 diabetes (a common disease).  Like PIDD, individuals with Type 2 
diabetes have a condition where the primary defect (in the case of diabetes, cells cannot 
uptake insulin) impacts other body systems and leads to comorbidities.  Additionally, the 
disease states are comparable in that neither can be cured, but with management, medical 
treatment enables the patient to live for decades.  Thus, management of routine life 
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activities while always in a chronic disease state comes to the forefront in terms of impact 
to HRQOL and well-being.  Presented below is a direct-to-consumer advertisement for a 
new drug treatment for Type 2 diabetes.  The biomedical statement in the promotion 
reads: “Trulicity, along with diet and exercise, may help lower your blood sugar and 
A1C.” (How Trulicity can help, 2017, para 1).   
The promotion goes on in the biomedical framework to comment on a clinical 
trial to demonstrate lower blood sugar and A1C levels: “In a study, the higher dose 
helped 78% of people and the lower dose helped 66% of people get to the A1C goal of 
below 7%.” (How Trulicity can help 2017, para 1).  Next, the patient is informed about 
the innovation of Trulicity, and how the innovation might cater to patient preferences for 
treatment with this statement:  
Trulicity is designed to be taken once a week, which may help you fit it into your 
 busy life.  You can take Trulicity any time of day, with or without meals.  Just 
 pick which day of the week will be your Trulicity Day and remember to keep 
 taking it that day, every week. (How Trulicity can help, 2017, para 4)  
The promotion is silent regarding impact on HRQOL and well-being.  However, 
Fisher, Tang, and Polonsky (2017) introduced their paper by commenting on the advent 
of medical products innovated for achieving glycemic control and the associated interest 
among, for example, researchers, FDA, and patients regarding measures of quality of life 
and well-being.  The authors pointed out that glycemic control is generally a primary 
measure but that patients and other stakeholders consider equally important the secondary 
or tertiary measures of quality of life (Fisher, Tang, & Polonsky, 2017). 
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Likewise, the literature and direct-to-consumer advertising demonstrate that 
medical product innovations in the treatment of PIDD still meet clinical criteria of 
boosting the immune system, while also offering patients flexibility to live their life; for 
example, to self-administer therapy wherever they might be physically located and at a 
time of their choosing. 
 The gap in knowledge this study aimed to fill is whether there were any 
differences in HRQOL and well-being between patients with PIDD who use medical 
products innovated for fewer needles sticks or for shorter infusion times versus those who 
do not.  Since patient preferences contributed to medical products manufacturers’ 
innovation of new medical products, this study was needed to understand whether the 
resultant innovated medical products improved HRQOL and well-being, as measured by 
PROMIS-29, for patients with PIDD.  
Problem Statement 
The problem I addressed is the gap in the literature concerning whether medical 
products innovated per patient preferences for fewer needles sticks and shorter infusion 
times resulted in improved HRQOL and well-being, as measured by PROMIS-29, for 
patients with PIDD.  Factors associated with poorer HRQOL include comorbidities, 
unemployment, stress, multiple infections, and PIDD diagnosis delay (Jiang et al., 2015).  
Factors associated with improved HRQOL include home-based therapy; treatment 
comfort, flexibility, convenience, and independence; shorter treatment duration and less 
impact/disruption to daily activities (e.g., school/work and social); and satisfactory 
immunoglobulin trough levels (Jiang et al., 2015; Vultaggio et al., 2015).   
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Additional to evaluating patients’ treatment preferences, researchers also 
evaluated patients’ satisfaction with treatment.  Espanol, Prevot, Drabwell, Sondhi, and 
Olding (2014) found that the majority of patients with PIDD (76%, n = 300) were pleased 
with their current treatment; however, those receiving SCIG (83%) were more pleased 
compared to those receiving IVIG (69%).  Additionally, Espanol et al. (2014) compared 
SCIG with IVIG in terms of impact on HRQOL measures of anxiety, depression, 
mobility, routine activity performance, pain, and self-care.  The researchers’ analysis 
revealed there was no difference in HRQOL (71.8% and 71.9%, respectively) as 
measured by the EQ-5D (Espanol et al., 2014).  Deshpande, Rajan, Sudeepthi, and Nazir 
(2011) noted that assessing patient-reported outcomes is an important component to 
understanding patient compliance with treatment, improvements to medical products, and 
better patient outcomes such as quality of life related to medical treatment.  Based on my 
review, the literature has not yet been expanded to present the changes in HRQOL and 
well-being as dependent variables to recent medical product innovations allowing for 
fewer needle sticks and offering shorter infusion duration using the PROMIS-29 
instrument in a population of patients with PIDD.  
Purpose of the Study 
The purpose of this quantitative study was to compare the mean differences in 
HRQOL and well-being as measured by PROMIS-29 for patients with PIDD who used 
medical product manufacturers’ innovative medical products designed to require (a) 
fewer needle sticks or (b) shorter infusion time to patients who did not use such products.  
The dependent variables were PROMIS-29 instrument measures of anxiety and 
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depression as proxies of HRQOL and participation in social roles/activities as a proxy of 
well-being (HealthyPeople.gov, 2017).  My overarching purpose is to help patients who 
have a chronic disease state which cannot be cured and can only be managed via a regular 
treatment routine to have optimal HRQOL and well-being.  The results of this research 
have the potential to add to the body of scientific knowledge and provide support for 
patient-reported outcomes of HRQOL and well-being as valid inputs in medical product 
development and FDA regulatory decision-making.   
Research Questions and Hypotheses 
Research Question 1: Is there a difference in the well-being proxy PROMIS score 
for “Ability to Participate in Social Roles/Activities” between patients with PIDD who 
report using medical products innovated to offer therapeutic dosing with one needle stick 
every 3 or 4 weeks compared to those who report using medical products innovated to 
offer therapeutic dosing with more than one needle stick every 3 or 4 weeks?   
H01: The mean differences are not statistically significant. 
Ha1: The mean differences are statistically significant. 
The independent variable was needle sticks, and the dependent variable was PROMIS 
score (Likert scale mean). 
Research Question 2: Is there a difference in the HRQOL proxy PROMIS score 
for “Anxiety” between patients with PIDD who report using medical products innovated 
to offer therapeutic dosing with one needle stick every 3 or 4 weeks compared to those 
who report using medical products innovated to offer therapeutic dosing with more than 
one needle stick every 3 or 4 weeks?   
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H02: The mean differences are not statistically significant. 
Ha2: The mean differences are statistically significant. 
The independent variable was needle sticks, and the dependent variable was PROMIS 
score (Likert scale mean). 
Research Question 3: Is there a difference in the HRQOL proxy PROMIS score 
for “Depression” between patients with PIDD who report using medical products 
innovated to offer therapeutic dosing with one needle stick every 3 or 4 weeks compared 
to those who report using medical products innovated to offer therapeutic dosing with 
more than one needle stick every 3 or 4 weeks?   
H03: The mean differences are not statistically significant. 
Ha3: The mean differences are statistically significant. 
The independent variable was needle sticks, and the dependent variable was PROMIS 
score (Likert scale mean). 
Research Question 4: Is there a difference in the well-being proxy PROMIS score 
for “Ability to Participate in Social Roles/Activities” between patients with PIDD who 
report using medical products innovated for shorter infusion time compared to those who 
report using medical products not innovated for shorter infusion time?   
Interpretation: Because infusion time depends on patient tolerance irrespective of 
product innovation, for this study shorter infusion time was defined as less than or equal 
to 4 hours and longer infusion time was defined as greater than 4 hours (Ponsford et al., 
2015). 
H04: The mean differences are not statistically significant. 
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Ha4: The mean differences are statistically significant. 
The independent variable was infusion time duration, and the dependent variable was 
PROMIS score (Likert scale mean). 
Research Question 5: Is there a difference in the HRQOL proxy PROMIS score 
for “Anxiety” between patients with PIDD who report using medical products innovated 
for shorter infusion time compared to those who report using medical products not 
innovated for shorter infusion time?   
Interpretation: Because infusion time depends on patient tolerance irrespective of 
product innovation, for this study shorter infusion time was defined as less than or equal 
to 4 hours and longer infusion time was defined as greater than 4 hours (Ponsford, et al., 
2015). 
H05: The mean differences are not statistically significant. 
Ha5: The mean differences are statistically significant. 
The independent variable was infusion time duration, and the dependent variable was 
PROMIS score (Likert scale mean). 
Research Question 6: Is there a difference in the HRQOL proxy PROMIS score 
for “Depression” between patients with PIDD who report using medical products 
innovated for shorter infusion time compared to those who report using medical products 
not innovated for shorter infusion time?   
Interpretation: Because infusion time depends on patient tolerance irrespective of 
product innovation, for this study shorter infusion time was defined as less than or equal 
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to 4 hours and longer infusion time was defined as greater than 4 hours (Ponsford, et al., 
2015). 
H06: The mean differences are not statistically significant. 
Ha6: The mean differences are statistically significant. 
The independent variable was infusion time duration, and dependent variable was 
PROMIS score (Likert scale mean). 
Theoretical Framework 
 The theoretical framework used for this dissertation was George Engel’s (1977) 
biopsychosocial model, which is found within medical sociology and derived from the 
understanding among sociologists and physicians, that there is an interplay between 
biology, culture, social determinants of health, and the environment which influence 
whether, and how, people become ill (also the duration, intensity, and type of illness 
manifestation) from a given cause.  George Engel (1977) introduced the biopsychosocial 
model as a counter to the biomedical approach toward the practice of medicine.  Engel 
posited that the biomedical model was inadequate as it reduced the patient to his or her 
body parts and biochemical elements.  However, Engel argued, the patient is a whole 
being with senses and experiences.  Thus, the patient is a composite of biological, 
psychological, and social systems and sub-systems, none of which exists in isolation from 
the others.   
Physicians use the biopsychosocial model as a model for patient interaction, and 
as a framework for how the physician can view the patient and provide care (Engel, 1977; 
Engel, 1980; Haveilka, Lcuanin, & Lcuanin, 2009).  Medical product manufacturers and 
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regulatory authorities can use this framework in a way that they can observe the patient 
who will use the medical products once approved.  In medical sociology, illness is 
described in the broader term encompassing sickness caused by microorganisms or 
physiologic malfunction (e. g. flu, diabetes, or HIV/AIDS) and illness related to daily 
living (e. g. depression, stress, or fatigue) (Cockerham, 1981).  Albrecht and Devlieger 
(1999) postulated via the disability paradox framework that people with debilitating 
illness can experience an excellent quality of life.  I used the disability paradox 
framework as a basis for including a well-being measure in this study (Albrecht & 
Devlieger, 1999; Fellinghauer, Reinhardt, Stucki & Bickenbach, 2012).  My use of the 
biopsychosocial model can help determine if consideration of patients’ perspectives, 
incorporated into drug development, results in better outcomes in terms of HRQOL and 
well-being.  
Nature of the Study 
I used quantitative methodology to analyze patient registry data from the United 
States Immunodeficiency Network (USIDNET) to understand mean changes in HRQOL 
and well-being as measured by the NIH sponsored PROMIS-29 instrument.  The 
objective for this study was to measure differences in HRQOL scores and well-being of 
patients with PIDD based on patient preferences for treatment; namely, number of needle 
sticks and infusion time using the biopsychosocial model framework to explain the 




Ability to participate in social roles/ activities: The ability to participate in social 
roles/activities bank of PROMIS questions focuses on feelings of well-being or thriving 
as individuals participate in their typical societal roles and social relationships (Bode, 
Hahn, DeVellis, & Cella, 2013). 
Anxiety: The anxiety bank of PROMIS questions focuses on feelings of fear, 
dread, and nervousness which might be accompanied by cardiovascular system response 
and dizziness (Schalet et al., 2016)  
Depression: The depression bank of PROMIS questions focuses on feelings of 
sadness, guilt, low self-worth, loneliness, and disinterest in life (“Depression: A Brief 
Guide,” 2017). 
Food and Drug Administration: As related to this dissertation, FDA is a 
governmental agency under the Department of Health and Human Services charged with 
protecting public health by ensuring the availability of safe, effective, and innovative 
medical products and advancing public health through provision of science-based, 
publicly available information (FDA, 2015c). 
Health-related quality of life (HRQOL/ HRQL): The subjective measure of patient 
perceptions of their physical, social, and emotional functioning with one or more chronic 
diseases (Elliott & Richardson, 2014). 
Patient-centered: An approach which encompasses the biopsychosocial 
theoretical framework in that it is inclusive of patients or their proxies (e.g., a caregiver, 
parent, or advocate; Kalra, 2014).  This approach involves considering patients’ and/or 
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proxy members’ opinions and contributions to decision-making in all aspects of care, 
from medical product development through regulatory approval to type of treatment 
prescribed by a medical practitioner and pharmacy provider (Kalra, 2014).  
Patient-reported outcomes (PRO): A self-assessed measure of health status which 
is independent of a clinical analysis or medical professional evaluation (Nicassio et al., 
2011). 
Perceived health: An individual’s subjective assessment of his or her biological, 
cultural, social, and psychological functioning which can be used as an indicator of 
patient satisfaction with his or her health and with medical treatments (Seeborg et al., 
2015) 
Primary immune deficiency disease (primary immune deficiency disorder): A 
group of rare genetic diseases in which components of the immune system are missing or 
defective, resulting in a tendency to have unusual infections which are more severe and 
last longer than in individuals with an intact immune system (IDF, 2016).   
Route of administration: The pathway by which medication is introduced to the 
body.  Injection routes of administrations discussed here include intramuscular (IM), 
intravenous (IV), and subcutaneous (SC).  Injection routes of administration of immune 
globulin (IG) for PIDD are described using the terms IMIG, IVIG, and SCIG (Kobrynski, 
2012). 
Well-being: A measure of how people are coping in a positive way and also 




I made two assumptions for this study.  The first assumption was that the 
USIDNET patient registry from which I obtained study data is representative of the 
general PIDD population in the United States and of the PIDD patient population whose 
treatment preferences informed drug innovation.  The second assumption was that the 
PROMIS-29 measures are relevant for the PIDD population. 
Scope and Delimitations 
Firstly, not all medical products are specified for pediatric patients.  Therefore, 
the study plan was to include patients who were 16 years old and older at the time they 
took the survey.  I used a liberal definition of adulthood to select the age 16 years and 
older.  The rationale stemmed from concerns regarding sample size due to the rareness of 
PIDD, and that each state defines its criterion of adulthood for various purposes.  For this 
study, age 16 represented the two states (New York and North Carolina) where criminal 
offenders would be tried in an adult court (National Conference of State Legislatures, 
2017).  Secondly, there are several categories of PIDD.  This study captured all the 
categories under the general heading PIDD and I did not segment according to PIDD 
subtype. 
Limitations 
Blome and Augustin (2015) presented views of the types of biases which exist 
when measuring changes in HRQOL prospectively and retrospectively.  The research 
proposed here is a retrospective study where researchers collect data only after an 
intervention.  Respondents can take the survey semiannually.  Retrospective studies are 
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subject to recall bias, where the respondent either recalls their past situation as being 
either better or worse than their current situation, based on how they feel when taking the 
assessment or a respondent reconstructs their response based on current feelings and 
assumptions about their past status (Blome & Augustine, 2015).  A second category of 
bias relates to how subjects respond to survey questions.  The tendency to answer in 
agreement, answer in disagreement, disregard questions deemed as not applicable to the 
subject’s situation, answer randomly, answer at the extremes, or answer in a manner the 
subject deems is more socially acceptable creates bias (Blome & Augustine, 2015).  
Blome and Augustine (2015) suggested a retrospective study even with the listed biases 
could be beneficial when one wants to understand patient views on treatment benefits.  
Fayers, Langston, and Robertson (2007) described response error in 
measurements of quality of life (QOL).  The authors posited that QOL bias is introduced 
regarding the frame of reference the subject uses when responding to the survey 
instrument (Fayers, Langston, & Robertson, 2007).  The frame of reference could be a 
comparison to: self, prior to illness; self, the previous time point in a longitudinal study; 
other patients with the same disease; patients with a different disease; and healthy 
subjects.  At each interval of measurement, the frame of reference can shift.  Upon testing 
for mean differences in subjects’ expressed frame of reference against QOL scores, there 
were statistically significant differences according to frame of reference (Fayers et al., 
2007).   
Lastly, the sample size was expected to be small due to the rareness of PIDD, and 
randomization was not possible.  Limitations were addressed via statistical analytical 
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methods additional to t-tests as warranted by the data.  Additionally, limitations are 
acknowledged in the methodology and conclusion chapters.  
Significance of the Study 
Information gained from this study could help the primary immunodeficiency 
community understand changes (hopefully improvements) in HRQOL and well-being 
parameters resulting from using different medical product innovations enabling 
flexibility. For example, patient perspectives can inform drug development and even the 
regulatory process for drug approval. Once the drug is developed and on the market, 
which of the patient perspectives (specifically related to social parameters measured with 
instruments measuring HRQOL and well-being parameters) changed because of using a 
given drug?  Such knowledge could be useful for refining drug development protocol and 
regulatory policy in the future. 
Summary 
In this chapter, I presented information about PIDD, the role of medical product 
manufactures as it relates to HRQOL and well-being, the relevance of PIDD to public 
health, and a theoretical lens through which PIDD can be viewed.  In the next chapter, I 
establish the basis for the study by reviewing existing literature and identifying gaps in 
the literature.  Some of the areas reviewed include the biopsychosocial model theoretical 





Chapter 2: Literature Review 
Introduction 
Medical products manufacturers have innovated therapies for patients with PIDD 
based on patient preferences for fewer needle sticks and a shorter infusion time with the 
goal of improving these patients’ HRQOL and well-being (Espanol et al., 2014; 
Kobrynski, 2012; Ponsford et al., 2015).  Since 2015, the IDF through USIDNET has 
been collecting HRQOL and well-being data on patients with PIDD through the 
PROMIS-29 survey instrument.  There is limited data showing whether therapies 
innovated for fewer needle sticks and shorter infusion time have an impact on HRQOL 
and well-being as measured by PROMIS-29.  The purpose of this quantitative study was 
to determine the mean differences in HRQOL and well-being using PROMIS-29 scores 
of patients with PIDD who are using medical product manufacturers’ innovative medical 
products allowing for (a) fewer needle sticks and (b) shorter infusion time compared to 
those who were not. 
 This literature review begins with the search strategy I used for locating literature.  
I then present the biopsychosocial model theoretical framework and supporting studies.  
Next, I present an extensive literature review of key variables and concepts.  Lastly, I 
conclude with the gap found in the literature which my study aimed to fill, and with a 
summary of the chapter.     
Literature Search Strategy 
Although the tone of the literature review is neutral and is based on the positivist 
tradition of biomedical research (see Wilson, 2000), it suggests the need to expand 
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beyond physiological parameters of biomedical research to include psychosocial 
parameters, along with patient experience (Mead & Bower, 2000).  The literature review 
was conceptual in nature, to demonstrate the ongoing paradigm shift of incorporating 
patient views in modern biomedical research (see Wilson, 2000).  I used the following 
questions to guide my literature search:  
 In patients with the same disease state and undergoing a standard protocol of 
treatment for it, why do some have better biomedical (e.g., controlled disease 
state as evidenced by laboratory blood chemistry measures) and psychosocial 
(e.g., self-reported days of feeling well/sick) outcomes than others?   
 What are the factors associated with better or worse outcomes?   
 How have researchers analyzed the relationship between social factors and 
medical outcomes?   
 What have researchers done to address medical outcomes related to social 
factors?   
 What research methods have been used in the past to determine associations 
between social parameters and medical outcomes? 
The literature search began on June 30, 2014.  My strategy included assessing key words 
in the Walden University Library Health Sciences Research databases.  The databases 
searched included MEDLINE with Full Text, CINAHL Plus with Full Text, ProQuest 
Nursing & Allied Health Source, PubMed, and Science Direct.  Additionally, a Thoreau 
multidatabase search was conducted.  The keywords used were chronic illness or chronic 
disease, well-being, AND genetic disorders; well-being AND primary immune; burden of 
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disease AND subcutaneous AND intravenous; bio-psychosocial model; treatment 
preferences AND subcutaneous AND intravenous; patient-focused; patient-centered; 
patient-reported outcomes; and PIDD.   
Then, I narrowed the search to include primarily peer-reviewed articles published 
in the years between 2008 and 2017, unless a seminal piece of literature added context to 
the review.  Because the medical product innovations being studied do not all have 
pediatric indications, I excluded articles which focused solely on children.  The focus of 
the dissertation was a rare genetic medical condition (PIDD) which, with treatment, is 
manageable for years and decades like a chronic disease (see Chapel et al., 2014).  Thus, 
I excluded literature which focused on terminal illnesses.  Because PIDD stems from a 
biological cause, I also excluded literature focusing on psychological disorders.   
I consulted timely nonscholarly works such as transcripts of the FDA’s patient-
centered drug development program as an endeavor to add clarity on patient perspectives 
(Coplan, Noel, Levitan, Ferguson, & Mussen, 2011).  FDA’s patient-centered drug 
development program encompassed a series of public meetings, each focused on a 
different medical condition.  Patients with a given disease spoke about their life with the 
condition.  Caregivers and individuals representing advocacy organizations spoke about 
their life as a caregiver or advocate of someone with the condition.  Participants shared 
their experiences with medical treatments utilized.  Participants also discussed their 
perspectives about clinical trials, and future treatment options (FDA, 2015a).  I reviewed 
transcripts from public meetings held inclusive of the years 2011-2016 for the rare and 
genetic diseases which involved a treatment regimen administered via the subcutaneous 
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or intravenous routes (FDA, 2017).  From the transcripts of polling questions and 
discussion points, I honed the idea of including well-being measures into the present 
study.  I also consulted the websites of advocacy organizations, such as International 
Patient Organization for Primary Immunodeficiencies (IPOPI) and Immune Deficiencies 
Foundation (IDF), and articles referenced on their websites to elucidate variables for 
consideration in the present study.  Lastly, I consulted websites such as Clinical 
Trials.gov, NIH, FDA, and National Organization for Rare Disorders (NORD). 
Theoretical Foundation 
The theoretical foundation used in this study was the biopsychosocial model.  
According to the tenets of this model, health and illness are not merely biological.  
Instead, health and illness involve the whole individual.  Thus, the contributions to health 
and illness include biological, psychological, and social parameters (Engel, 1980).  This 
holistic framework includes biological (i.e., organs, organ systems, biochemistry, vital 
signs, and physical presentation); psychological (i.e., attitude, behaviors, emotions, and 
preferences); and social (i.e., where and with whom one navigates through daily life at 
home, at school, at work, at places of worship, relationships, participation) elements 
(Engel, 1980).  I designed my study to use the biopsychosocial model to relate the 
biomedical variables of medical product innovation with the psychosocial variables of 
HRQOL and well-being.     
Immunoglobulin replacement therapies developed by medical product 
manufacturers for PIDD are only approved by FDA once they are demonstrated via 
clinical trials with biomedical endpoints to be safe and effective (Melamed et al., 2012).  
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The biomedical endpoints include biological measures such as IG blood levels and the 
metabolism process, monitoring site of injection and systemic reactions, and measuring 
and assessing changes in infection rate (Dashti-Kavidaki et al., 2009; Melamed et al., 
2012).  Patients, caregivers, and advocates express their desire for improved treatments.  
They serve as agents stimulating medical product manufacturers to support research 
aimed at soliciting and evaluating patient feedback regarding satisfaction with current 
treatment, and preferences for improvements in treatment offerings (Doward, 
Gnanasakthy, & Baker, 2010).  FDA regulators seek to inform their regulatory decision-
making using biomedical endpoints from clinical trials and input from patient-reported 
outcomes collected during clinical trials (U.S. Department of Health and Human 
Services, 2009).  A search of the literature revealed studies on the PIDD population 






Review of Patient-Reported Outcomes Studies on Primary Immune Deficiency Disease 
Reference Objective and 
population 
Variables Patient-reported outcomes by 
measurement instrument 
Results 
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administration 
IG serum level 
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Satisfaction with home-based treatment 
interference was higher for SCIG than 
for IVIG. 
Satisfaction with IVIG treatment 
interference was higher in a hospital 
setting than in a home setting. 
There was no difference between route 
of administration and place of 
administration on patients’ satisfaction 
with therapy-related problems. 
Satisfaction with therapy setting was 
optimal for home-based SCIG. 
QOL related to route and place of 
administration revealed no statistically 






Reference Objective and 
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Variables Patient-reported outcomes by 
measurement instrument 
Results 
Espanol et al. 
(2014) 
Patient preferences 




survey completed by 300 
patients from 21 different 
countries.  
Current treatment 






Impact of PIDD on 
HRQOL 
Impact of treatment on 
HRQOL  
Physical and psychosocial health 
measures by 
12-Item Short Form Health Survey 
(SF-12v2) 
HRQOL 
10-Item Short Form Health Survey 
(SF-10v2) 
 
Self-care, usual activities, pain/ 
discomfort, anxiety/ depression by 
EuroQOL five Dimensions 
Patients preferred self-administration 
versus administration by a healthcare 
professional. 
Patients also preferred home versus 
hospital administration, therapy which 
enabled monthly versus weekly or 
every two weeks treatment, fewer 
needle sticks, and shorter infusion 






Depression and anxiety 
level experienced by 
patients with PIDD and 
how much depression and 




survey was extended to 
PIDD patients at a 
university division of 
pulmonary, allergy, and 






Amounts of anxiety and 
depression experienced 
and attributed to PIDD 
diagnosis 
Hamilton Depression Rating Scale 
(HAM-D) 
 
Amount of depression experienced 
Amount of depression attributed to 
PIDD 
 
Hamilton Anxiety Rating Scale 
(HAM-A) 
 
Amount of anxiety experienced 
Amount of anxiety attributed to 
PIDD 
Patients with PIDD had median HAM-
D scores comparable to the US 
population. 
 
Patients receiving IVIG therapy in the 
home or in a clinic had significantly 
higher HAM-D scores than those 
receiving SCIG at home. 
Patients who had healthcare 
professional administered therapy had 
higher HAM-D scores than those who 
self-administered. 
Higher HAM-D scores were associated 
with adverse effects from IGRT. 
Patients receiving IVIG attributed 
higher amounts of their anxiety to their 







Reference Objective and 
population 
Variables Patient-reported outcomes by 
measurement instrument 
Results 
Jorgensen et al. 
(2014) 
HRQOL in patients with 
selective IgA deficiency 
(SIgAD) and to determine 
factors leading to poor 
HRQOL. 
 
Icelandic patients with 
SIgAD (n=33) were 
matched with randomly 
selected age and gender-
matched Icelandic 
controls (n=96) with 















Mental health  
 
Patients with SIgAD reported lower 
global HRQOL than did the control 
group of persons with normal immune 
globulin levels.  The differences were 








centered care by 
calculating the relative 
importance of immune 
globulin treatment 
attributes to patients. 
 
Web-enabled choice-
format conjoint survey 








Route of administration 
Self- or healthcare professional 
administration 
Frequency of administration 
Location of administration 




Patients indicated preferences for 
monthly versus weekly administration, 
home setting versus doctor’s office/ 
hospital/ clinic, shorter versus longer 
treatment durations, and fewer needle 
sticks of IG treatment relative to 
alternative choices. 
Seeborg et al. 
(2015) 
Total of 1526 patients 
(61.2%), with PIDD from 










Perceived health status 
 
Patients perceived their health as 
excellent or very good (30%), good 







Reference Objective and 
population 
Variables Patient-reported outcomes by 
measurement instrument 
Results 
Perceived health was associated with 
age, gender, education level, and 
employment status. 
Patients with access to IVIG therapy 
and specialty care were more likely to 
perceive their health as excellent or 
very good. 
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Disease clinical severity perception 
relative to other patients with the 














HRQOL scores were low, and were 
also lower than those reported by 
generally healthy people, and by 
people with other chronic diseases 
(except heart failure). 
Female gender and older age was 












Reference Objective and 
population 
Variables Patient-reported outcomes by 
measurement instrument 
Results 
Vultaggio et al. 
(2015) 
To evaluate changes in 
biomedical and patient-
reported parameters in 
response to a shift from 




study included 50 patients 
in Italy with PIDD who 
also were concurrently 
taking part in a PIDD 
medical product clinical 
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Life Quality Index 
Impact of the IgG treatment on 
daily activities 
 
Visual Analogue Scale 
Perception of general health 
Treatment with SCIG did not 
significantly improve HRQOL in 














 As noted in Chapter 1, I mention the disability paradox as a secondary framework 
to explain possible association of independent and dependent variables.  The disability 
paradox framework is an explanation for why individuals whom an outside observer 
would consider to have low HRQOL based on appearance might self-assess a better 
HRQOL, even compared with healthy subjects (Albrecht & Devlieger, 1999; 
Fellinghauer et al., 2012). 
Biopsychosocial Model 
 George Engel introduced the biopsychosocial model as a counter to the 
biomedical approach toward the practice of medicine.  Engel (1977) posited that the 
biomedical model was inadequate and reductionist as it reduced the patient to his or her 
body parts and biochemical elements.  Engel posited that the patient is a whole being that 
senses and experiences.  The patient is a composite of biological, psychological, and 
social systems and sub-systems, none of which exists in isolation from the others.  The 
biopsychosocial model has been used as a model for patient-physician interaction; and as 
a framework for how the physician can view the patient and provide care (Engel, 1977; 
Engel, 1980; Haveilka et al., 2009).  This framework can be used by medical product 
manufacturers and regulatory authorities for how they view the person who will use the 
medical products once approved.  
Why selected for this study? I developed the logic model presented in Figure 1 
to show how elements of the biopsychosocial model related to the variables under study 




psychosocial inputs.  Biomedical inputs include biochemical effects of the PIDD disease 
state and of immunoglobulin replacement therapy (e.g., immunoglobulin levels in the 
blood, vital signs, and infection), or how patients reported that they felt (e.g., malaise).  
These dependent variables are represented but greyed out in the logic model, because 
they are not the focus of this study.  Psychosocial inputs include the patient-reported 
outcome dependent variables of HRQOL, and well-being.  These are shown as green in 
the logic model and these are the focus of this study.  The intervention is medical product 
innovation because of patient treatment preference inputs and biomedical inputs.  The 
outcome of the intervention would hopefully be a change in patient-reported outcomes of 
HRQOL and well-being, for the better, along with maintained or improved clinical 
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Figure 1. Logic model. 
 Chronic disease defies the biomedical concept of a malfunctioning body which 
can be restored to function via purely medical or physiological intervention (i.e. if blood 
pressure is too low, position the body with head raised and feet lowered and administer a 
medical product which makes the blood vessels contract, and if blood pressure is too 
high, administer medications to lower it) because chronic disease has no cure.  Chronic 
disease extends beyond the local physiological parameters of the body and it encroaches 
into life by having impact on the social (e.g. engagements, making plans, going out, and 
playing with children), and practical (e.g. being able to work, manage a household, self-




Literature Review of Studies Which Used the Biopsychosocial Model 
 None of the PIDD articles located in the literature search specifically named the 
biopsychosocial model.  However, the literature demonstrates that the model has been 
used to explain the relationships of independent and dependent variables for other chronic 
disease states, and in some cases for rare diseases.  A summary of that literature is shown 
in Table 2.  Elliott and Richardson (2014) studied the biopsychosocial model in persons 
with epilepsy.  An outside observer aligned with the biomedical model might intuit that 
the greatest improvement to HRQOL for persons with epilepsy is to have few or no 
seizures.  Thus, any medical products which could achieve few or no seizures, along with 
fewer side effects, would also improve HRQOL.  However, persons with epilepsy have 
psychosocial manifestations of epilepsy, such as a greater tendency toward depression 
and anxiety which impact ability to attend to requirements of work, school, and social 
relationships (Elliott & Richardson, 2014).  Elliott and Richardson (2014) argued that due 
to a biomedical focus, the psychosocial aspects of epilepsy generally remain untreated.  
The researchers established independent variables aligned with the biopsychosocial 
model; namely, biomedical (e.g. age, gender, comorbidities, and number of doctor visits); 
psychological (e.g. diagnosed depression and/ or anxiety, and number of visits to mental 
health professionals); social (e.g. educational attainment, annual income, marital status, 
and community belonging).  The dependent variables were self-rating of health and 
mental health status, and satisfaction with life.  Both the independent and dependent 
variables were organized from the Canadian Community Health Survey.  The researcher 




biomedical model, the biopsychosocial model explained more of the variance in QOL, 
where Whole Set Correlation R2 = 24.8% for the biomedical model and 55.0% for the 
biopsychosocial model, respectively.  Additionally, the researchers evaluated biomedical, 
psychological, and social elements individually and found that the psychological element 
(Partial Set Correlation (PSC) R2 = 30.4%), and the social element (PSC R2 = 26.8%) 
explained more of the variance in QOL than the biomedical element alone (PSC R2= 
14.3%).  Thus, the authors concluded that the biomedical element such as controlling 
seizures is important; however, it is not the only element contributing to HRQOL.  
Further, the authors called for a patient-centered approach which also brings 
psychological and social practitioners into holistic treatment regimens for individuals 
with epilepsy.  Kalra, Gupta, and Unnikrishnan (2016) argued the value of the 
biopsychosocial model in terms of availability of insulin preparations available to 
patients.  When the biomedical requirements of, say, blood glucose and hemoglobin A1c 
are met, the patient and their physician could select an insulin therapy regimen which fits 
into that individual patient’s psychological preferences (such as injection frequency and 
timing, meal frequency and size, ability to self-inject, and glucose monitoring), and social 
preferences (such as lifestyle, infusion location which provides privacy, and work 
schedule).  The authors noted that soliciting and implementing patient, caregiver, and 
advocate treatment preferences along with biomedical measures, is essential for long-
term disease management (Kalra, 2014; Kalra et al., 2016).        
 Baranyi et al. (2013) used the biopsychosocial framework to understand social 




alpha treatment for hepatitis C, and those who did not as a way of predicting who would 
develop depression; and, therefore, to develop preventive measures for such patients (see 
Table 2).  Baranyi et al. (2013) included a social context (i.e. social support) and set out 






Use of Biopsychosocial Model in Literature and How These Studies Compare to PIDD 
Reference Disease state Comparison with literature on PIDD 
Baranyi et al. (2013) Hepatitis C Used the biopsychosocial framework to understand social and 
psychological differences between patients who became 
depressed during interferon alpha treatment for hepatitis C and 
those who did not.  Like IGRT, interferon treatment for 
hepatitis C is administered by subcutaneous injection.  
Adherence to a medical product injection regimen is necessary 
for viral reduction (Ward & Kugelmas, 2005).   
 
Lasker, Sogolow, Short, and Sass 
(2011) 
Organ transplant Used the biopsychosocial model to select HRQOL variables 
and assess the demographic, biomedical, psychological, and 
sociological factors the researchers believed related to quality 
of life.  Lasker et al. determined whether those variables 
differed before and after transplant; and also determined which 
variables were most important. 
Verderese, Graham, Holder-
McShane, Harnett, and Barton 
(1993) 
Gaucher’s disease Measured subjective and objective symptom relief in response 
to enzyme replacement therapy in patients with Gaucher’s 
Disease.  Like PIDD, Gaucher’s disease is a rare genetic 
disorder mitigated by outpatient replacement therapy 





Criticism of the Biopsychosocial Model. Criticisms of the biopsychosocial 
model include that the model does not stand on its own, but is instead an extension of the 
biomedical model with psychological and social factors added on; constructs are not well 
defined; and the model does not explain the origin of disease (Haveilka et al., 2009). 
Primary Immune Deficiency Disease 
 The prevalence of infectious diseases in the early part of the twentieth century 
masked PIDD.  As scientific progress in medicine and public health interventions brought 
infectious diseases under control, medical cases of chronic diseases became more 
prevalent.  Cases of PIDD also became observable to the medical community due to the 
manifestation of unusual and severe infectious diseases which could be readily treated for 
individuals with an intact immune system (Chapel et al., 2014; Costa-Carvalho et al., 
2014).  Though there are several types of treatment available for PIDD (e. g. blood stem 
cell transplant, antibiotics therapy, or gene therapy), the mainstay treatment is immune 
globulin G (IgG) replacement therapy; referred to throughout this dissertation as IGRT 
(Chapel et al., 2014; Dashti-Khavidaki et al., 2009).  Genetic defects of the immune 
system results in defective cells, antibodies, and / or complement.  Immunity resides in 
the bone marrow and in the blood.  As such, the immune system is spread throughout the 
body.  Thus, a defect in a gene coding for an immunity cell, antibody, or the complement 




The Role of the Patient 
 Management of PIDD is complex in that it involves a regimen of aseptic medicine 
transfer into IV bags and/ or syringes, injection site cleansing, and medication injection 
into the intravascular system.  Management of PIDD is also burdensome as it involves 
making time to visit an infusion clinic to receive medication, or making room in the home 
for supplies and time in one’s schedule to administer therapy (Melamed et al., 2012).  
However, adherence to the infusion routine is essential for warding off infection 
(Bienvenu et al., 2016).  IDF is a patient organization providing education, advocacy, 
research opportunities, and outreach to and on behalf of people with primary immune 
deficiency disease (IDF, n. d.).  IDF is a key voice in the United States through which 
researchers, regulatory agencies, and medical products manufacturers can understand the 
needs of the patients with PIDD. 
The Role of the FDA 
 The FDA, like other ministries of health around the world, protects and promotes 
public health via regulation provided to manufacturers of medical products.  The premise 
is regulatory oversight will result in safe and effective medical products which will 
produce positive outcomes for patients.  Yet, people with the same disease state and 
undergoing the same treatment for it have varying experiences and outcomes (Wilson and 
Cleary, 1995).   
 Through the Patient-Focused Drug Development initiative, FDA officers are 
examining burden of disease, treatment preferences, and ways to improve health 




a series of meetings, each covering a different disease state (Lejbkowicz, Caspi, & Miller, 
2012; Muhlbacher, Juhnke, Beyer, & Garner, 2016).  FDA’s responsibility is to ensure 
that the benefits of drugs outweigh the risks, understand how patients view benefits and 
risks of treatments, and guide researchers, via the regulatory process, to appropriate end 
points to measure how well these drugs are working (FDA, 2015a).   
The Role of the Medical Product Manufacturers 
 Immune globulin G is a highly purified plasma protein.  Manufacturers produce 
IgG by purifying plasma collected from donors.  The proprietary manufacturing process 
each manufacturer uses includes fractionation steps, viral deactivation, excipients 
addition, and pH and temperature adjustments (Chapel et al., 2014).  For initial approval 
by FDA, manufactures of IGRT are responsible for ensuring the key biomedical factors 
of safety (e.g. no viral transmission from the IG to patient), efficacy (e.g. reduced 
infections), and tolerability (e.g. few or no adverse reactions) are confirmed in humans 
via clinical trial (Chapel et al., 2014).  After initial approval by FDA, manufacturing 
status, changes, safety reports, and post-marketing clinical and non-clinical commitments 
or requirements are each reported to FDA on various frequencies such as batch-to-batch, 
quarterly, and annually. 
 Medical products manufacturers have incorporated patient perspectives into 
therapy improvements with the aim of improving treatment satisfaction and quality of 
life, and the FDA has approved these therapies.   
 The first such improvement was developing therapy alternatives enabling patients 




administration in the home.  Research showed improvements in HRQOL (Garduff & 
Nicoloay, 2006).  The next medical product innovation, in response to patient expression, 
was development of therapies with reduction in the number of needle sticks and shorter 
infusion times while maintaining self-infusion at home (Espanol et al., (2014).  
Preliminary analysis suggested that these changes to medical product innovation would 
result in reduced burden; therefore, improved quality of life (Ponsford et al. 2015; 
Wasserman, 2014).   
Treatment Options 
 The three routes of IGRT administration include needle injections into the muscle, 
veins, or under the skin.  Intramuscular injection (IMIG) is a rarely used route of 
administration.  In a study of patients receiving IVIG, causes of adverse reactions (e.g. 
fever and chills) included infection, infusion reactions, infusing too rapidly, switching 
medications, first infusion, and a long-time interval between injections (Dashti-Khavidaki 
et al., 2009).  The first IGRT was delivered subcutaneously in 1952 and was thereafter 
delivered intramuscularly until 1980.  From 1980 to the present IVIG has been prominent 
and as recently as 1991, SCIG has begun to make a resurgence (Haddad et al., 2012).  
Researchers evaluating the biomedical effects of SCIG noted systemic adverse events 
were reduced while the effects (e.g. burning, itching, and swelling) were localized to the 
site of injection (Haddad et al., 2012; Melamed et al., 2012).  
Burden of Treatment 
 Hirsch, Walker, Chang, and Lyness (2012) studied chronic diseases in adults aged 




medical illness, is reduced by the presence of optimism and increased by the presence of 
pessimism.  The researchers’ hypothesis was realized by the results and this led to their 
suggestion to implement moderating factors such as training patients to have positive 
thoughts and to foster meaningful relationships, and developing clinical health 
interventions which shift the patient’s frame of mental reference to a more optimistic 
viewpoint (Hirsch et al., 2012).   
Verderese et al. (1993) measured subjective and objective symptom relief in 
response to enzyme replacement therapy in patients with Gaucher’s Disease.  Like PIDD, 
Gaucher’s disease is a rare genetic disorder (where glucocerebrosidase enzyme is lacking 
resulting in the systemic buildup of the lipid glucocerebroside inside macrophage white 
blood cells and organs such as the spleen, liver, and bone marrow) which is mitigated by 
outpatient replacement therapy administered intravenously.  After each enzyme 
replacement treatment, Verderese et al. (1993) recorded subjective patient perceptions on 
reduction of bruising (measured by increased platelet counts), chronic fatigue (measured 
by increased hemoglobin concentration), and gastrointestinal protrusion (measured by 
reduced abdomen size) and found the subjective perception of symptom relief often 
preceded the laboratory measurement of the corresponding parameter.  Additionally, self-
concept, self-esteem, self-image, and mood were reported to have improved due to 
patients’ having more energy and reduced abdominal size, leading to more confidence in 




Patient-Focused Drug Development and Patient-Centered Treatments 
 As described in the FDA Prescription Drug User Fee Act Patient-Focused Drug 
Development (2013) announcement in the Federal Register, FDA personnel initiated a 
series of public meetings under its Patient-Focused Drug Development initiative.  Each 
meeting focused on a specific disease, with involved FDA staff, patients, caregivers, and 
advocacy organizations.   The FDA personnel used mixed-methods research 
methodology and gathered information through questionnaires, polls, written comments, 
and focus group discussions regarding daily life, lived experience with the disease, the 
symptoms of greatest impact, current medical and non-medical treatment regimens in 
use, and opinions about clinical trials.  Theoretically, this patient-centered approach 
would be an input to the regulatory guidance provided to medical product manufacturers 
for new and already commercialized products as well as to the regulatory decision-
making used by the Agency for initial approval (FDA, 2015a).   
 Patient reported outcomes are increasingly solicited via surveys presented to 
participants in clinical studies intended to show drug safety and efficacy.  However, 
results may not be reflective of the general population who will use the drug upon its 
commercialization due to the selection criteria used for clinical trial participation.   
Fleurence et al. (2013) argued the importance of including the patient perspective into 
clinical studies.  The researchers used as examples Alzheimer’s dementia and a 
comparison of two heart surgery interventions.  In the former, the clinical endpoint would 
typically be changes representing improved cognitive ability.  However, patient 




the latter example, the clinical endpoint could be decreased complications and increased 
longevity.  However, patient preference was for relief of chest pain (Fleurence et al., 
2013).  Related to PIDD, immunoglobulin replacement therapy safety and efficacy 
clinical endpoints typically are measured by IgG trough levels, change in the number and 
types of infections, change in the number and types of infections requiring 
hospitalization, and site of injection issues (Dashti-Khavidaki et al., 2009).  However, 
one of the challenges to drawing conclusions regarding patient preferences compared to 
the clinical endpoints measured via laboratory analysis and/ or mathematical calculation 
is they are inherently subjective and require interpretation and translation to objective 
measures.  Conjoint analysis and Best-Worst Scaling (BWS) are two statistical methods 
for elucidating patient medical treatment preferences and moving from qualitative to 
quantitative.  This enables medical product manufacturers to have a quantitative basis for 
assessing patient-reported endpoints and also developing next generation products.  
Additionally, such measures of patient preferences are useful to regulators in their review 
of new product applications and ongoing surveillance of commercial medical products 
(Johnson & Zhou, 2016; Morel, et al., 2016).  Conjoint analysis has its origin in 
consumer research aimed at understanding preferences for various attributes of a product 
offering (Kinter, Prior, Carswell, & Bridges, 2012).  In the health care setting, conjoint 
analysis and BWS can be used to help medical product manufacturers, and the FDA 
understand the relative importance of treatment attributes, and risk to benefit tradeoffs 
acceptable to patients and/ or caregivers (Kinter et al., 2012).  Mohamed et al. (2012) 




and 66 parents, all in the United States, regarding treatment provider (self or healthcare 
professional), frequency (every other week or weekly), location (home or clinic), needle 
sticks (four or one), and treatment duration (6 hours or 2 hours).  Treatment preferences 
were selected based on a qualitative pre-test with a sample of nine patients and parents 
using open-ended interview questions.  In the study, route of administration was 
predominately IVIG (59.9%) versus SCIG (41.1%).  Both patients and parents preferred a 
home setting, monthly infusions, fewer needle sticks, and shorter duration.  In terms of 
preference for treatment, both patients and parents considered least important whether the 
patient self-infused treatment or a healthcare provider administered the treatment.  For 
patients, location was the most important and for parents, frequency was most important.  
Regarding relative importance to patients of the individual therapy attributes and trade-
offs, with increased treatment frequency, fewer needle sticks and shorter duration became 
more important.  Espanol et al. (2014) elucidated PIDD treatment preferences from 216 
patients and 84 caregivers via a multinational online survey using conjoint analysis.  In 
contrast with Mohamed et al. (2012), route of administration (e.g. IVIG, SCIG, and 
other) was a distinct category along with patients and caregivers (referred to as parents by 
Mohamed et al.) and was analyzed as such by Espanol et al. (2014).  Respondents 
represented 21 countries on the continents of Africa, Asia, Australia (including New 
Zealand), Europe, North America (excluding the US), and South America.  Intravenous 
(53%) and subcutaneous routes (45%) of administration were represented.  Patients on 
IVIG received therapy an average of every 23 days in a clinical (75%) setting or at home 




six days.  Patients and caregivers were asked to respond to the following categories of 
preferences: (a) self-administration versus administration by a health professional; (b) 
monthly, every-other weekly, or weekly treatment frequency; (c) home or clinical 
treatment location; (d) one, two, or four needle sticks per treatment; and (e) two, four, or 
six-hour therapy duration.  Across the IVIG and SCIG routes of administration, both 
patients and caregivers preferred monthly treatments, a home environment, one or two 
needle sticks, and two-hour therapy duration.  SCIG patients and caregivers significantly 
preferred self-administration while the preference for IVIG among patients and 
caregivers was not statistically significant.  Both sets of authors indicated the importance 
of assessing PIDD patient and caregiver preferences and representing these preferences in 
treatment offerings to fulfill unmet needs in terms of HRQOL.  Interestingly, both studies 
were supported by medical product manufacturers, and this suggests an understanding 
that gauging patient and caregiver preferences is an important input to their decisions 
about next generation therapies.  Hollin, Paey, and Bridges (2015) further illustrated the 
usefulness of quantifying patient treatment preference.  This study was initiated by 
caregivers to children with Duchene Muscular Dystrophy.  The patient advocacy 
organization called Parent Project Muscular Dystrophy (PPMD) engaged the Duchene 
Muscular Dystrophy community in gathering treatment preferences and, with FDA’s 
blessing, modeled their approach after FDA’s Patient-Focused Drug Development 
initiative, with the exception that PPMD used conjoint analysis and best-worst scaling 
(BWS) to quantitate treatment preferences.  Hollin et al. (2015) compared two methods 




used to collect preferences.  Their study was also intended to provide evidence the 
methodology can be useful for regulatory decision-making in terms of medical product 
and treatment risk-to-benefit and tradeoffs patients and caregivers are willing to make 
(Hollin, Paey, & Bridges, 2015).  This study underscores the role of patients and 
caregivers with their advocacy organizations, medical products manufacturers, and FDA 
in facilitating the provision of patient-centered treatments (Hollin et al., 2015). 
Patient-Reported Outcomes: HRQOL and Well-being 
As discussed, one of the goals for measuring patient preferences for treatment is 
to demonstrate treatment tradeoffs and risk-to-benefit of treatment attributes patients and 
caregivers are willing to make (Hollin et al., 2015).  However, another goal for measuring 
patient preferences for treatment is to ultimately improve patient HRQOL and well-being.  
As with other diseases, researchers studying patients with PIDD have argued for the 
development of a HRQOL instrument specific to overall primary immune deficiency as 
well as specific variants of the disease (Quinti et al., 2016). 
Studies located for this review measured HRQOL and well-being associated with 
patient satisfaction with current treatment for PIDD over time; changes in treatment 
regimen; and aspects of treatment which change perceived health.  Kobrynski (2012) 
reviewed nine studies which compared route of administration and location of 
administration (home versus hospital).  The studies took place in Europe (three each in 
Sweden and Germany, and one in Norway and Denmark) and in North America (USA 
and Canada), from 1995 to 2011.  Seven studies examined changes in HRQOL and well-




clinical setting (e.g. hospital or clinic) to immunoglobulin delivery by the subcutaneous 
route of administration in a home setting.  Generally, study results revealed treatment 
satisfaction with SCIG as measured via the Life Quality Index (LQI) instrument.  Other 
improved HRQOL measures included general health perception, family activities, and 
general health as measured by Short Form-36 (SF-36) and Child Health Questionnaire-
Parent Form 50 (CHQ-PF50).  Among patients receiving IVIG, one study showed some 
viewed SCIG in the home as inconvenient.  One study comparing SCIG in the hospital/ 
clinic versus SCIG in the home revealed patient satisfaction and feeling of independence 
with home infusions of SCIG.  Finally, authors of one study compared treatment 
regimens which could reduce home-based SCIG infusion times and found high 
satisfaction with rapid infusion.   
Jiang et al. (2015) also reviewed the literature regarding HRQOL in patients with 
PIDD.  The researchers focused on treatment regimen satisfaction (i.e. route and location 
of administration) measured via commonly used survey instruments (see Table 1).  Jiang 
et al. also included studies which made comparisons between patients with PIDD and 
healthy study subjects, and studies which compared patients with PIDD to patients with 
other chronic diseases.  Factors associated with poorer HRQOL included comorbidities, 
employment status, stress, multiple infections, and PIDD diagnosis delay.  Other factors 
associated with improved HRQOL included home-based therapy; treatment comfort, 
flexibility, convenience, and independence; shorter treatment duration and less impact/ 
disruption to daily activities (e.g. school/ work, and social); and satisfactory 




(2014) showed the majority of patients with PIDD (76%, n=300) were pleased with their 
current treatment; however, those receiving SCIG (83%) were more pleased compared to 
those receiving IVIG (69%).  Relating SCIG and IVIG treatment to HRQOL, as assessed 
by the EQ-5D, measures of anxiety, depression, mobility, routine activity performance, 
pain, and self-care revealed there was no difference in HRQOL (71.8% and 71.9%, 
respectively).  Overall, HRQOL was found to be poorer in patients with the common 
variable immune deficiency form of PIDD than in the US population as measured by EQ-
5D and SF-36 instruments (Espanol et al., 2014; Tabolli et al., 2014).  In contrast, 
assessment of HRQOL by SF-36 in PIDD patients with a deficiency of immune globulin 
A (n=32) compared with age and gender matched controls (n=63) revealed no 
statistically significant difference (Jorgensen et al., 2013).  Likewise, a study focused 
specifically on HRQOL, anxiety and depression in patients with PIDD (n=33) as 
measured by HAM-D and HAM-A found that levels were similar to the general US 
population. 
The synthesis of the abovementioned studies reveals that HRQOL has been 
measured as a dependent variable according to patient preference for treatment, such as 
route of administration (intravenous versus subcutaneous), place of administration 
(clinical setting versus home environment), and infusion duration using a standard SCIG 
route versus a newly innovated enzyme-facilitated SCIG route.  The HRQOL measures 
were assessed using various commonly used instruments.  Additionally, the literature 
revealed sources of variables leading to higher or lower HRQOL scores with moderating 




changes in HRQOL and well-being as dependent variables to recent medical product 
innovations allowing for fewer needle sticks and offering shorter infusion duration using 
the PROMIS-29 instrument in a population of patients with PIDD.  This is the area where 
my dissertation can begin to close this gap.       
PROMIS Instrument 
 The PROMIS instrument is a set of standardized and validated questionnaire 
items used for measuring QOL.  Developed under the National Institutes of Health’s 
Roadmap Initiative, PROMIS can be utilized across a number of chronic disease states, 
including for genetic diseases (Cohen & Biesecker, 2010).   
Summary and Conclusions 
I introduced the literary basis for this study of mean changes in HRQOL and well-
being for patients with PIDD who use medical products innovated with consideration of 
patient preferences for treatment; specifically, the number of needle sticks and infusion 
time.  Additionally, I presented a literary basis for use of the biopsychosocial framework 
to explain the relationship between the dependent and independent variables.  In the 
following chapter, I present the research questions and further elucidate study variables 




Chapter 3: Research Method 
Introduction 
The purpose of this study was to examine whether the incorporation of patient 
preferences for treatment into medical product innovation results in improved HRQOL 
and well-being for patients with PIDD.  Use of statistical tools such as conjoint analysis 
to quantify patient preferences for treatment provides medical products manufacturers 
with data for their development of next-generation products aimed at improving patient 
experience as measured by HRQOL and well-being scales (Mohamed et al., 2012; Morel 
et al., 2016).  Patient preferences also inform FDA leaders in their regulatory decision-
making.  For example, FDA leaders consider the biomedical elements of a next-
generation medical product in terms of safety and efficacy of metabolism once in the 
body as well as the psychosocial elements related to the daily life of patients and 
enhancing quality and well-being (Johnson & Zhou, 2016).   
Through the literature review process, I learned the following: (a) HRQOL and 
well-being have been measured for patients with PIDD; (b) patients with PIDD have been 
queried regarding treatment preferences, and some of these preferences have been 
measured using standard instruments which measure HRQOL, such as SF-36; and (c) 
manufacturers of medical products have developed therapies to align with patient 
preferences for treatment.  As discussed in Chapter 1, type 2 diabetes is one mainstream 
example where medical product manufacturers have innovated a variety of therapies in 
response to patient preferences for treatment in terms of dosing flexibility, dosing with or 




Schroeder, & Dougherty, 2012).  Similarly, manufacturers of medical products have 
innovated a variety of therapies for patients with PIDD.  The gap that I observed in 
reviewing the literature regarding PIDD is that there has not yet been a study showing 
that patient treatment preferences for fewer needle sticks and shorter infusion time 
translated into improved HRQOL and well-being, as measured by the PROMIS-29 
instrument, for patients taking medical products innovated per these preferences.    
I divided this chapter into sections which cover the research design and rationale, 
the PIDD population studied, study design, determination of sampling size and methods 
for procuring a sample, and data analysis methods.  Additionally, I discuss protection of 
human subjects, data handling, and threats to internal and external validity.  The 
reliability and validity of the PROMIS survey instrument were discussed in Chapter 2. 
Research Design and Rationale 
Using a cross-sectional study design, I sought to examine whether patient 
preferences for fewer needle sticks and shorter infusion time translated into differences in 
HRQOL and well-being for patients with PIDD who were using medical products 
innovated according to those preferences.  The independent variables were needle sticks 
and infusion time.  Based on the medical product each patient reported using at the time 
of data collection, I assigned patients into two categories: those who used the medical 
product innovated for each of the independent variables under study and those who did 
not (see Table 3).  Thus, patients who reported using a medical product innovated to need 
fewer needle sticks were compared to those patients who reported using a medical 




medical products which allow for a shorter infusion time were compared to those patients 
who reported using medical products which do not entail a shorter infusion time.  I 
compared the mean PROMIS-29 scores for HRQOL (e.g., anxiety and depression) and 
well-being (e.g., ability to participate in social roles/activities) for each patient group.   
I used PROMIS instrument measures for understanding well-being and HRQOL.  
The proxy measure for well-being was “Ability to Participate in Social Roles/Activities” 
while the proxy measures for HRQOL were “Anxiety” and “Depression”; all of these 
PROMIS measures were the dependent variables (Barile et al., 2013; HealthyPeople.gov, 
2017).  The potential confounding variables of age, gender, education level, and 
employment status related to HRQOL have been studied in patients with PIDD (see 
Seeborg et al., 2015; Tabolli et al., 2014).  In this study, age, median household income, 
and gender were part of the secondary dataset I used and were, therefore, available for 
analysis.   
Methodology 
Population 
The population data used for this research included all patients who had a 
confirmed diagnosis of PIDD and who were using IGRT.  Additional inclusion criteria 
included patients who gave consent and completed the PROMIS-29 instrument via the 
USIDNET (collaboration between the NIH and the IDF) and who also had medical 
information on file in IDF’s patient registry.  As of October 2017, the total population for 
inclusion consideration was 162 patients.  Any patient who met the criteria for 




Sampling and Sampling Procedures 
I received a written invitation from IDF to submit a query to USIDNET (see 
Appendix A) after I had contacted IDF regarding any QOL data they might have from 
patients with PIDD.  The query was generated based on my response to questions from 
which I could select categories of information.  The query template also included fields 
into which I could write provide additional information or make requests.  My query 
served as the basis for establishing the study population (see Appendix B).   
When selecting a sample, two of the considerations were effects size and also the 
alpha and beta levels.  The effects size (Cohen’s d), which I obtained from the literature 
(see Bienvenu et al., 2016) and also from informal calculations of standard deviations of 
independent variables, is 0.16.  This effect size is small (Cohen, 1988).  Regarding alpha 
and beta levels, these should be selected so that the sample size is large enough to have 
enough power to detect a statistically significant difference and so that the null 
hypothesis is not falsely rejected or maintained (Banerjee, Chitnis, Jadhav, Bhawalkar, & 
Chaudhury, 2009).  I selected an alpha of 0.05 and a beta of 0.20 to establish power equal 
to 80%.   
I used the entire population of individuals meeting the inclusion criteria.  IDF, via 
USIDNET, solicits additional patient participation every 6 months, in spring and fall (M. 
Goldsmith, personal communication, February 9, 2017).  After I obtained Walden 
University IRB approval, I e-mailed IDF staffers and requested that they run my query 
again to potentially gain more participants.  I also submitted a second query for patients 




comparisons on attributes common between those who did and those who did not 
complete the PROMIS-29 survey in order to potentially generalize HRQOL and well-
being results.  Permission to submit a query and use resultant information is located in 
Appendix A. 
Research Questions and Hypotheses 
The overarching question was whether addressing patient preferences for 
treatment through medical product innovation resulted in better outcomes from a 
psychosocial perspective, and whether any of these outcomes were also influenced by 
gender, median household income, or age.  MacKinnon and Luecken (2008) described 
various types of other variables according to their relationship to the independent and/or 
dependent variable.  The authors mentioned that mediating variables are caused by the 
independent variable and cause the dependent variable; and moderating variables as those 
which aid in understanding the circumstances for when the independent and dependent 
variables are related (MacKinnon & Luecken, 2008).  MacKinnon and Luecken (2008) 
also defined a confounding variable as one which is related to both the independent and 
dependent variables and thus changes the relationship between the two; and covariates, 
which can be related to the independent and / or the dependent variable but do not change 
the relationship.  In my study, consideration of gender, age, and median household 
income could explain the circumstances under which patients have a greater sense of 
well-being and HRQOL when using a medical product innovated according to a given 
patient-reported outcome.  The variables might also be related to selection of medical 




confounding variables.  There were two additional potential confounding variables over 
which I thought I might have control since data fields were available by query within the 
secondary data available from IDF.  The first variable related to active disease present at 
the time the patient completed the PROMIS-29 assessment.  Bienvenu et al. (2016) found 
that patients with active disease had lower HRQOL scores compared to those without.  
Thus, via the literature, active disease showed a link to my dependent variables which 
measure HRQOL.  Results could be confounded if levels of active disease differ across 
my independent variable (patient preference for treatment).  The second confounding 
variable potentially was treatment-related symptoms or adverse events associated with 
the route of administration (SCIG or IVIG) and influence on HRQOL (Espanol et al., 
2014).  Administration via the subcutaneous route tends to produce localized effects such 
as swelling, redness, and pain around the site(s) of needle insertion.  Administration via 
the intravenous route tends to result in systemic effects such as fever and malaise 
(Kobrynski, 2012).  However, both routes of administration can produce local and/or 
systemic effects.  When I compared dependent variables for HRQOL for infusion time, 
results might have been confounded by treatment-related symptoms and/ or adverse 
events because the SCIG group was directly compared to the IVIG group.  The groups 
were not homogenous across the two routes of administration.  However, in practice, 
patients move across the routes of administration according to their individual needs, 
preferences, and doctors’ recommendation (Espanol, et al., 2014, Kobrynski, 2012).  For 
those patients who moved across therapies and routes of administration, I used the 




Table 3 shows the link between patient preferences for treatment and medical product 
innovation that were assessed. 
Table 3 
Operationalization of Variables 
Patient preference for treatment, with 
literature reference 
Medical Product Innovation Comparison 
Groupsa 
Fewer needle sticks 





   
Shorter infusion time 
Espanol et al., (2014, p. 622) 
Melamed et al., (2012, p. 453) 




aThe mean for each dependent variable was compared. 
Data Analysis Plan 
The statistical methods originally planned for addressing the research questions 
included two-tailed t-tests for independent samples, and possibly correlation and 
regression analyses (logistic regression for categorical variables, and multiple regression 
for quantitative variables), and ANCOVA in order to test the difference between means 
(see Table 3) while controlling for age, gender and median household income.  The 
assumptions were that the data are homogenous and normally distributed; thus, these 
attributes could be tested using parametric statistics. 
Research Question 1: Is there a difference in the well-being proxy PROMIS score 




report using medical products innovated to offer therapeutic dosing with one needle stick 
every 3 or 4 weeks compared to those who report using medical products innovated to 
offer therapeutic dosing with more than one needle stick every 3 or 4 weeks?   
H01: The mean differences are not statistically significant. 
Ha1: The mean differences are statistically significant. 
The independent variable was needle sticks, and the dependent variable was PROMIS 
score (Likert scale mean). 
Research Question 2: Is there a difference in the HRQOL proxy PROMIS score 
for “Anxiety” between patients with PIDD who report using medical products innovated 
to offer therapeutic dosing with one needle stick every 3 or 4 weeks compared to those 
who report using medical products innovated to offer therapeutic dosing with more than 
one needle stick every 3 or 4 weeks?   
H02: The mean differences are not statistically significant. 
Ha2: The mean differences are statistically significant. 
The independent variable was needle sticks, and the dependent variable was PROMIS 
score (Likert scale mean). 
Research Question 3: Is there a difference in the HRQOL proxy PROMIS score 
for “Depression” between patients with PIDD who report using medical products 
innovated to offer therapeutic dosing with one needle stick every 3 or 4 weeks compared 
to those who report using medical products innovated to offer therapeutic dosing with 
more than one needle stick every 3 or 4 weeks?   




Ha3: The mean differences are statistically significant. 
The independent variable was needle sticks, and the dependent variable was PROMIS 
score (Likert scale mean). 
Research Question 4: Is there a difference in the well-being proxy PROMIS score 
for “Ability to Participate in Social Roles/Activities” between patients with PIDD who 
report using medical products innovated for shorter infusion time compared to those who 
report using medical products not innovated for shorter infusion time?   
Interpretation: Because infusion time depends on patient tolerance irrespective of 
product innovation, for this study shorter infusion time was defined as less than or equal 
to 4 hours and longer infusion time was defined as greater than 4 hours (Ponsford et al., 
2015). 
H04: The mean differences are not statistically significant. 
Ha4: The mean differences are statistically significant. 
The independent variable was infusion time duration, and the dependent variable was 
PROMIS score (Likert scale mean). 
Research Question 5: Is there a difference in the HRQOL proxy PROMIS score 
for “Anxiety” between patients with PIDD who report using medical products innovated 
for shorter infusion time compared to those who report using medical products not 
innovated for shorter infusion time?   
Interpretation: Because infusion time depends on patient tolerance irrespective of 




to 4 hours and longer infusion time was defined as greater than 4 hours (Ponsford, et al., 
2015). 
H05: The mean differences are not statistically significant. 
Ha5: The mean differences are statistically significant. 
The independent variable was infusion time duration, and the dependent variable was 
PROMIS score (Likert scale mean). 
Research Question 6: Is there a difference in the HRQOL proxy PROMIS score 
for “Depression” between patients with PIDD who report using medical products 
innovated for shorter infusion time compared to those who report using medical products 
not innovated for shorter infusion time?   
Interpretation: Because infusion time depends on patient tolerance irrespective of 
product innovation, for this study shorter infusion time was defined as less than or equal 
to 4 hours and longer infusion time was defined as greater than 4 hours (Ponsford, et al., 
2015). 
H06: The mean differences are not statistically significant. 
Ha6: The mean differences are statistically significant. 
The independent variable was infusion time duration, and dependent variable was 








List of Variables 






Medical product promotional or 
label claim for the number of 
injection sites per dosing 
frequency 
Categorical 0 = 1 needle stick 
per 3-4 weeks 
1 = 2 or more needle 
sticks per 3-4 weeks 
    
Infusion 
Duration 
Medical product promotional or 
label claim for time per infusion 
Categorical 0 = infusion time 
less than or equal to 
4 hours 
1 = infusion time 






A domain in the PROMIS-29 
validated instrument in this 





A domain in the PROMIS-29 
validated instrument in this 








A domain in the PROMIS-29 
validated instrument in this 













Gender Patient reported gender Dichotomous 0 = male 




Median income in US dollars 








PROMIS-29 is a general instrument intended for persons aged 18 years and older.  
The instrument asks four questions from each of seven domains (ability to participate in 
social roles and activities, anxiety, depression, fatigue, pain interference, physical 
function, sleep disturbance) and one question on a pain intensity scale.  Except for 
physical function, the domains have a time element and ask for a response based on the 
past seven days.  For each question within a domain, the participant can select a value 
from 1-4.  Thus, the lowest score in any singular domain is 4, and the highest score is 20 
from the responses, and based on a t-score (PROMIS, 2011). 
For the variable anxiety, and depression, (negatively worded), a lower t-score is 
better than average.  For the variable ability to participate in social roles: (positively 
worded) a lower t-score is worse than average.  The average t-score is based on the U.S. 
population and is normalized to 50.0 (PROMIS, 2011). 
Data Handling 
After I received IRB approval from Walden University on 28 September 2017 
(approval number 09-28-17-0389089), I submitted a query for preexisting data from 
USIDNET through IDF.  This query netted PROMIS-29 patient data from 2015 through 
May, 2017, and general patient registry data from April, 2008 through July, 2017.  IDF 
provided the query results in an email containing two Excel spreadsheets.  The data were 
downloaded onto a personal laptop, coded, and entered into SPSS.  Data files were stored 
on a personal password protected One Share cloud drive, and the original email was 




Protection of Human Subjects 
Data obtained for this study were obtained from USIDNET already de-identified. 
Dissemination of Findings 
 Study findings will be presented to Walden University to support partial 
fulfillment of academic requirement for a doctorate in public health.  Although not 
requested, findings might be disseminated to IDF and their patient, caregiver, and 
advocate membership.  The results of this study could be presented for publication in 
peer-reviewed journals such as Journal of Clinical Immunology, BMC Public Health, or 
Health Affairs. 
Threats to Internal Validity 
 Threats to internal validity include the following biases which could have been 
present in the populations I studied (namely, patients with PIDD who are listed in the IDF 
patient registry and completed the PROMIS-29 survey, and who did not complete the 
PROMIS-29 survey): (a) recall bias; (b) survey response bias (e.g. a tendency for a more 
positive or more negative response to survey questions or questions about health; (c) 
selection – history bias where patients using a given medical product might differ from 
one another; and (d) selection – maturation where patients who previously took the 
survey (which IDF solicits for completion twice annually) differ from those who have not 
previously taken the PROMIS-29 survey, or patients who have used multiple types of 
IGRT medical products versus those who have not (Blome & Augustine, 2015; 
Frankfort-Nachmias & Nachmias, 2008).  In the analysis phase, upon receiving IRB 




Threats to External Validity (Generalizability) 
 The population of patients with PIDD could not be randomized.  Thus, patients 
consenting to take the PROMIS-29 instrument might not represent patients in IDF’s 
registry who did not take the PROMIS-29 survey.  Likewise, patients with PIDD in IDF’s 
registry, of whom my population was a subset of this broader population, might not 
represent the entire population of patients with PIDD globally.  Ultimately, the goal was 
to generalize across all patients with PIDD.  Upon data analysis, I looked to identify 
possible threats to external validity by comparing my dataset of individuals in IDF’s 
patient registry who completed the PROMIS-29 survey with those in the same registry 
who did not. 
Summary 
In this chapter, I presented the methods for understanding potential relationships 
between patient preferences for treatment (desire for fewer needle sticks, and a shorter 
infusion time) serving as the basis of manufacturers’ innovations in medical products 
subsequently approved by the FDA and patients’ well-being (ability to participate in 
social roles) and HRQOL (anxiety and depression) were presented.  A query of all 
USIDNET patient registry participants who gave consent to complete a PROMIS-29 
survey netted a non-randomized population of 162 participants in the three available 
study years 2015-2017.  A query of the same patient registry from 2008 – 2017 netted a 
non-randomized population of 1,939 participants available for comparison.  In the 
following chapter, statistical methods used to analyze data, and the results and meaning 




needle sticks was optimized upon examining the data, and how patients were categorized 




Chapter 4: Results 
Introduction 
The purpose of this dissertation was to compare the mean differences in HRQOL 
and well-being as measured by PROMIS-29 for patients with PIDD who used medical 
product manufacturers’ innovative medical products designed to have (a) fewer needle 
sticks and (b) shorter infusion time to patients who did not use such products.  I used a 
secondary dataset from IDF to address the research questions.  The six formulated 
research questions had the following structure: 
Needle Sticks: Is there a difference in X between patients with PIDD who report 
using medical products innovated to offer therapeutic dosing with fewer needle sticks 
every 3 or 4 weeks compared to those who report using medical products innovated to 
offer therapeutic dosing with more needle sticks every 3 or 4 weeks? 
Where X is (a) the well-being proxy PROMIS-29 score for “Ability to Participate 
in Social Roles/ Activities,” (b) the HRQOL proxy PROMIS-29 score for “Anxiety,” or 
(c) the HRQOL proxy PROMIS-29 score for “Depression.”  Additionally, I defined fewer 
needle sticks per 3 or 4 weeks as 1-8.  This marks a change from my definition, given in 
Chapters 1 and 3, of fewer needle sticks as 1 needle stick.  This change in definition from 
1 needle stick to fewer needle sticks accounts for patient choice to deliver less volume to 
a single infusion site (single needle stick) by using up to four needles to infuse 
simultaneously into four sites per infusion session, as allowed by the instructions on the 




maximum of four sites (hence four needles) would encounter eight needle sticks in 3 or 4 
weeks.  I defined more needle sticks per 3 or 4 weeks as greater than 8 needles.     
Infusion Time: Is there a difference in X between patients with PIDD who report 
using medical products innovated for shorter infusion time compared to those who report 
using medical products not innovated for shorter infusion time?   
Where X is (a) the well-being proxy PROMIS-29 score for “Ability to Participate 
in Social Roles/ Activities,” (b) the HRQOL proxy PROMIS-29 score for “Anxiety,” or 
(c) the HRQOL proxy PROMIS-29 score for “Depression.”  Additionally, shorter 
infusion time was defined as 1-4 hours, and longer infusion time was defined as greater 
than 4 hours. 
The null and alternate hypotheses for each question, as well as the independent 
and dependent variables were as follows: 
H0: The mean differences were not statistically significant. 
Ha: The mean differences were statistically significant. 
Independent variables: needle sticks, infusion time. 
Dependent variable: PROMIS score (Likert scale mean). 
Data analysis occurred October 12-November 18, 2017 after receipt of Walden 
IRB approval on September 28, 2017 (approval number 09-28-17-0389089) and upon 
receipt of datasets from IDF on October 12, 2017.  IDF had already granted approval on 
October 20, 2016 (see Appendix A) and cosigned a revised Data Use Agreement with me 




In this chapter, I will address how I prepared the dataset for analysis.  I will also 
present my results.  At the end of the chapter, I will include a summary of key points. 
Data Collection 
On September 28, 2017, I sent an e-mail to IDF requesting a refresh to the dataset 
corresponding to my original query to USIDNET (see Appendix B) in order to have 
PROMIS-29 data inclusive of the Spring 2017 issuance of the survey.  Additionally, I 
submitted a second query to USIDNET to obtain a dataset of individuals over the age of 
18 years who had not completed a PROMIS-29 survey.  This second query was 
additional to the plan I outlined in Chapter 3.  I submitted the second query for the 
purpose of noting similarities and differences (see Tables 5 and 6) between individuals in 
the patient registry who had completed a PROMIS-29 survey and those who had not. 
Inclusion/Exclusion Criteria 
The dataset of individuals who had completed a PROMIS-29 survey through 
Spring 2017 included 162 subjects.  Two of the 162 subjects received therapy via the 
intramuscular route instead of by either the subcutaneous or the intravenous route of 
administration.  Although I included the two subjects in the data comparison with those 
individuals who did not complete a PROMIS-29 survey, I excluded these individuals 
from the data analysis supporting my research questions.  Seven of the 162 subjects who 
completed a PROMIS-29 survey reported they were not using any immunoglobulin 
medical products.  I considered that these seven individuals could be comparison controls 
for the PROMIS-29 dependent variables; however, there were too few individuals for 




research question data analysis, I included them in the comparison with individuals who 
did not complete a PROMIS-29 survey.  The total number of subjects included in the 
analysis of my research questions was 153, representing 162 subjects minus nine 
excluded subjects.   
The dataset of individuals who had not completed a PROMIS-29 survey included 
1,939 subjects.  The age range included 62 individuals who were 17 years old, and all 
others were aged 18 and older.  The individuals who took the PROMIS-29 survey were 
aged 18 years and older.  Therefore, the 62 individuals who were 17 years of age were 
excluded, leaving a total of 1,877 subjects aged 18 years and older in the analysis. 
Adding Context to the Medical Product Innovation Categorical Values 
I originally planned to use medical product labeling to determine fewer versus 
more needle sticks.  As such, I determined that one needle stick every 3 or 4 weeks could 
suffice as the operationalization of the concept term “fewer.”  However, as I analyzed the 
dataset, I noted that some patients indicated the interval of days in which they infused a 
medical product.  Therefore, a patient infusing a product at the allowed rate of once every 
14 days, and using up to four injection sites allowed on the medical product labeling, 
would infuse using eight needles per month.  A patient who infused the same medication 
daily as allowed by the medical product labeling would use 30 or more needles per 
month.  The dataset revealed that patients who reported an infusion interval reported 
intervals of 1, 3, 4, 7, 14, 21, 25, 28, 30, or 42 days.  Thus, when an individual provided 
interval of infusion, I categorized him or her according to this information along with 




needle stick in my research question with my dataset, I had to increase the number of 
needlesticks representing “fewer” to eight needle sticks.  Thus, I defined more needle 
sticks as more than eight. 
Demographics 
As mentioned in Chapter 3, for the purpose of my dissertation research, my 
dataset consisted of the entire population of individuals who had taken the PROMIS-29 
survey.  However, this population of PROMIS-29 survey takers is a subset of all patients 
in IDF’s patient registry.  In order to support generalizability to the entire registry, I 
assessed available data which were common to all individuals in the patient registry in 
order to compare those who took the PROMIS-29 survey and those who did not.  Table 5 
shows demographics of individuals in the patient registry segmented into whether or not 













Comparison Demographics of Individuals Who Took the PROMIS-29 Survey and Those 






























































   
 
Gender and Race. The majority of the individuals in both groups were White 
females.  However, the population of individuals who took the PROMIS-29 survey was 
less balanced in terms of gender (79.6% female/ 20.4% male) compared with those in the 
registry who had not taken the PROMIS-29 survey (56.6% female/ 43.4% male).  The 
same applied to race, where nearly all of the individuals who took the PROMIS-29 
survey were White (99.4%), compared with those who did not take the PROMIS-29 




gender and race were equally distributed among the PROMIS-29 and non-PROMIS-29 
individuals in the patient registry.   
A chi-square test of independence was conducted between gender and PROMIS-
29 survey status.  All expected cell counts were greater than five.  There was a 
statistically significant association, and the null hypothesis that there was no association 
between gender and whether or not individuals had taken the PROMIS-29 survey was 
rejected.  Thus, χ2(1) = 32.476, p < .005.  The association was small, Cramer’s V =.126 
(Cohen, 1988).  Gender was not equally distributed between the two populations.   
A chi-square test of independence was conducted between race and PROMIS-29 
survey status.  Two cells (16.7%), Asian and Native American for those who had taken 
the PROMIS-29 survey, had expected counts less than five.  According to Yates, Moore, 
and McCabe (1999) if the number of cells with expected counts less than five is not more 
than 20% and if no single cell has an expected count less than one, the chi-square statistic 
might still be considered valid.  There was a statistically significant association, and the 
null hypothesis that there was no association between race and whether or not individuals 
had taken the PROMIS-29 survey was rejected.  Thus, χ2(5) = 24.973, p < .005.  The 
association was small, Cramer’s V =.127 (Cohen, 1988).  I determined to perform the 
chi-square test again after collapsing the number of race categories by combining Asian, 
Black, and Native American into a single category.  This time, all expected cell counts 
were greater than five.  Both sets of chi-square results were similar.  Again, there was a 




24.618, p <.005.  The association was small, Cramer’s V = .126.  Race was not equally 
distributed between the two populations. 
Route. Of the individuals reporting whether they received their IGRT regimen by 
IM, IV, SC, or None (i.e. they were not receiving IGRT medication), the population of 
PROMIS-29 survey takers were split roughly 50:50 between the IV and SC routes.  
Whereas, those who had not taken the PROMIS-29 survey were split between the 
majority using IV, followed by those who were not receiving IGRT, and lastly by the SC 
route.  Notably, while all individuals who had taken the PROMIS-29 survey reported, the 
524 missing values for those who had not taken the PROMIS-29 survey might have 
skewed the results.   
A chi-square test of independence was conducted between PROMIS-29 survey 
status and route of administration.  Two cells (25.0%), the IM route of therapy 
administration, had expected counts less than five.  According to Yates, Moore, and 
McCabe (1999) if the number of cells with expected counts less than five is not more 
than 20% and if no single cell has an expected count less than one, the chi-square statistic 
might still be considered valid.  Because my results did not meet this requirement, I used 
the two-tailed Fisher’s Exact test to determine whether there was a statistically significant 
difference between those who had taken the PROMIS-29 survey and those who had not 
taken the PROMIS-29 survey as regards route of therapy administration.  The results 
indicated that there was a statistically significant difference between the PROMIS-29 
survey takers and the other individuals in the patient registry as regards route of therapy.  




significant association and the null hypothesis was rejected (p = <.001, df = 3, Fisher’s 
Exact Test = 76.464). 
Disability. More than half of individuals in both groups reported having no 
disability (e.g. normal activity, and a range of none to some evidence of disease); 
followed by partial disability (e.g. ranging from ability to care for self but inability to 
carry out normal activities to requiring extensive care, and frequent medical care); and 
the fewest reported full disability (e.g. very ill, specialized care, and hospitalization).  
Though the percentages of the range of disability varied across those who took the 
PROMIS-29 survey versus those who did not, the results of a two-tailed Fisher’s Exact 
Test failed to reject the null hypothesis that there is no difference between two sets of 
individuals in terms of disability (p = .166, df = 2, Fisher’s Exact Test = 3.562). 
Individuals who completed a PROMIS-29 survey were also compared to those 
who did not in terms of chronological age and age at PIDD symptom onset, age at 
diagnosis, age at initiation of IGRT, and IGRT infusion interval.  These comparisons are 










Comparison Characteristics of Individuals Who Took the PROMIS-29 Survey and Those 
Who Did Not Take the PROMIS-29 Survey 





















































































































 Results shown in Table 6 reveal the mean age of individuals who completed the 
PROMIS-29 survey was 14 years older than those in the patient registry who did not.  A 
Mann-Whitney U test was run to determine if there were differences in age between those 
who took the PROMIS-29 survey and those who did not.  Distributions of age values 
were considered by visual inspection and were not similar.  Age values for those who 
took the PROMIS-29 survey (mean rank = 196.03) were statistically significantly higher 
than for those who did not take the PROMIS-29 survey (mean rank = 132.66), U = 
5,416.000, z = 4.080, p = <.001.  Additionally, those who took the PROMIS-29 survey 
were on average nine years older when symptoms appeared.  A Mann-Whitney U test 
was run to determine if there were differences in PIDD symptom onset between those 
who took the PROMIS-29 survey and those who did not.  Distributions of PIDD 
symptom onset age values were considered by visual inspection and were not similar.  
PIDD symptom onset age values for those who took the PROMIS-29 survey (mean rank 
= 179.17) were statistically significantly higher than for those who did not take the 
PROMIS-29 survey (mean rank = 134.70), U = 4,910.000, z = 2.862, p = .004. 
As a result of older age at symptom onset, on average, those who took the PROMIS-29 
survey also were 18 years older when diagnosed and 16 years older when they started 
IGRT.  A Mann-Whitney U test was run to determine if there were differences in age at 
PIDD diagnosis between those who took the PROMIS-29 survey and those who did not.  
Distributions of age at PIDD diagnosis were considered by visual inspection and were not 
similar.  Age at PIDD diagnosis values for those who took the PROMIS-29 survey (mean 




PROMIS-29 survey (mean rank = 131.43), U = 5,721.000, z = 4.811, p < .001.  Likewise, 
a Mann-Whitney U test was run to determine if there were differences in age at the start 
of IGRT between those who took the PROMIS-29 survey and those who did not.  
Distributions of age at the start of IGRT were considered by visual inspection and were 
not similar.  Age at the start of IGRT for those who took the PROMIS-29 survey (mean 
rank = 196.13) was statistically significantly higher than for those who did not take the 
PROMIS-29 survey (mean rank = 132.65), U = 5,419.000, z = 4.085, p < .001. 
The mean delay in diagnosis (I defined this as the difference between the mean 
age at symptom onset and the mean age at diagnosis) was twice as long for those who 
took the PROMIS-29 survey (18 years) compared with those who did not take the 
PROMIS-29 survey (nine years).  Lastly, the mode for infusion interval was 7 days for 
those who took the PROMIS-29 survey (suggesting a greater proportion of individuals 
who use the SCIG route of administration), versus 28 days for those who did not take 
PROMIS-29 (suggesting a greater proportion of individuals who use the IVIG route of 
administration).  Aligned with Table 5, comparing across the two groups, these data 
support that a greater proportion of individuals who took the PROMIS-29 survey were 
using the SCIG route of administration (i.e. generally more frequent administration 
ranging from daily, to every few days, weekly, or every 14 days) and a greater proportion 
of individuals who did not take the PROMIS-29 survey were using the IVIG route of 
administration (i.e. generally monthly administration).  A Mann-Whitney U test was run 
to determine if there were differences in interval of days of IGRT infusion between those 




days interval were considered by visual inspection and were not similar.  The IGRT 
infusion days interval for those who took the PROMIS-29 survey (mean rank = 96.97) 
was statistically significantly shorter than for those who did not take the PROMIS-29 
survey (mean rank = 144.65), U = 2,444.000, z = -3.169, p = .002.  
Analysis of Research Questions 
 In Chapter 3 I outlined a plan for using two-tailed independent t-tests to address 
my research questions.  Additionally, I planned to use ANCOVA to analyze age, and 
median annual income as covariates.  During the course of analysis, I found my data did 
not always meet some of the requirements regarding outliers, normality, and 
homogeneity of variances, even when I did a log10 or a square root transformation.  
Therefore, for each question I describe when assumptions were not met and the 
alternative methods applied. 
 Additionally, as I mentioned in Chapter 3, PROMIS-29 scores are written as a t-
score where the average, based on the U.S. population, is 50.0.  Each individual score 
was presented as an average t-score with a ± standard error.  In order to simplify the 
analyses, I used the PROMIS-29 scoring manual to convert the t-scores back to the Likert 
raw scores (PROMIS, 2015).  
Hypothesis 1 – Needle Sticks and Well-being (Ability). The null hypothesis for 
research question 1 was that there would be no difference in mean PROMIS-29 “Ability 
to Participate in Social Roles/ Activities” scores for patients with PIDD who used 
medical products innovated for fewer needle sticks versus those who used medical 




A total of 92 individuals were categorized as having fewer needle sticks, and 51 
individuals were categorized as having more needle sticks.  I ran a two-tailed independent 
t-test to determine if there were mean differences in ability to participate in social roles/ 
activities in those taking the innovative medical products compared to those who were 
not.  There were outliers (see Figure 2) in the data, as assessed by inspection of a boxplot.  
Therefore, a Mann-Whitney U test was also conducted. 
 






PROMIS-29 scores were normally distributed as determined by skewness and 
kurtosis (.009 and -.498, respectively for fewer needle sticks; and -.320 and .285, 
respectively for more needle sticks) values between ±1, and by inspection of a histogram 
and Q-Q plot.  There was homogeneity of variances as assessed by Levene’s test for 
equality of variances (p = .197).   
A two-tailed independent t-test revealed individuals using medical products 
innovated for fewer needle sticks (M = 11.79, SD = 3.946) did not have statistically 
significant different levels of well-being/ ability to participate in social roles/ activities 
compared to individuals using medical products which were not innovated for fewer 
needle sticks (M = 12.08, SD = 3.725), M = -.285, 95% CI [-1.620, 1.050], t (141) = -
.422, p = .674.   
Additionally, a Mann-Whitney U test revealed median PROMIS-29 scores for 
“Ability to Participate in Social Roles/ Activities” did not differ significantly for patients 
with PIDD who used medical products innovated for fewer needle sticks (Median = 
12.00) compared to those who did not (Median = 12.00), U = 2782.000, z = 0.252, p = 
.801. 
 Hypothesis 2 – Needle Sticks and HRQOL (Anxiety). The null hypothesis for 
research question 2 was that there would be no difference in mean PROMIS-29 
“Anxiety” scores for patients with PIDD who used medical products innovated for fewer 
needle sticks compared to those who used medical products which were not innovated for 




A total of 92 individuals were categorized as having fewer needle sticks, and 51 
individuals were categorized as having more needle sticks.  An independent t-test was run 
to determine if there were mean differences in anxiety in those taking the innovative 
medical products compared to those who were not.  There were no outliers in the data, as 
assessed by inspection of a boxplot.   
PROMIS-29 scores were fairly normally distributed as assessed by skewness and 
kurtosis values (-.070 and -1.160, respectively for fewer needle sticks, and .396 and -
.412, respectively for more needle sticks) between ±1, and inspection of a histogram and 
a Q-Q plot.  There was homogeneity of variance as assessed by Levene’s test for equality 
of variances (p = .095).  Individuals using medical products innovated for fewer needle 
sticks (M = 9.50, SD = 3.421) did not have statistically significant different levels of 
anxiety, HRQOL/ anxiety than individuals using medical products not innovated for 
fewer needle sticks (M = 8.73, SD = 3.020), M = .775, 95% CI [-.359, 1.908], t (141) = 
1.351, p = .179. 
Additionally, according to the Mann-Whitney U test, median PROMIS-29 scores 
for Anxiety did not differ significantly for patients with PIDD who used medical products 
innovated for fewer needle sticks (Median = 10.00) compared to those who did not 
(Median = 8.00), U = 2420.500, z = -1.125, p = .260. 
Hypothesis 3 – Needle Sticks and HRQOL (Depression). The null hypothesis 
for research question 3 was that there would be no difference in mean PROMIS-29 
“Depression” scores for patients with PIDD who used medical products innovated for 




for fewer needle sticks.   
A total of 92 individuals were categorized as having fewer needle sticks, and 51 
individuals were categorized as having more needle sticks.  I ran an independent t-test to 
determine if there were mean differences in depression in those taking innovative medical 
products compared to those who were not.  There were no outliers in the data, as assessed 
by inspection of a boxplot.  PROMIS-29 scores were fairly normally distributed as 
determined by skewness and kurtosis values (.456 and -.523, respectively for fewer 
needle sticks, and .365 and -1.019, respectively for more needle sticks) between ±1, and 
inspection of histograms and Q-Q plots.  There was homogeneity of variances as assessed 
by Levene’s test for equality of variances (p = .084).  Individuals using medical products 
innovated for fewer needle sticks (M = 8.86, SD = 3.839) did not have statistically 
significant different levels of HRQOL/ depression than individuals using medical 
products not innovated for fewer needle sticks (M = 8.00, SD = 3.225), M = .859, 95% CI 
[-.395, 2.113], t (141) = 1.354, p = .178. 
Additionally, a Mann-Whitney U test revealed median PROMIS-29 scores for 
Depression did not differ for patients with PIDD who used medical products innovated 
for fewer needle sticks (Median = 9.00) compared to those who did not (Median = 8.00), 
U = 2,471.000, z = -.933, p = .351. 
Hypothesis 4 – Infusion Time and Well-being (Ability). The null hypothesis for 
research question 4 was that there would be no difference in mean PROMIS-29 “Ability 
to Participate in Social Roles/ Activities” scores for patients with PIDD who used 




products which were not innovated for shorter infusion time.  A total of 71 individuals 
were categorized into having shorter infusion times, and 72 individuals were categorized 
into having longer infusion times.  A Welch t-test was run to determine if there were 
differences in ability to participate in social roles between shorter infusion times and 
longer infusion times due to the assumption of homogeneity of variance being violated, 
as assessed by Levene’s test for equality of variances (p = .027).  Additionally, visual 
inspection of a boxplot of the data revealed outliers.  Data were normally distributed 
based on skewness and kurtosis values (-.541 and .514, respectively for shorter infusion 
time, and .251 and -.547, respectively for longer infusion time) between ±1, and 
inspection of histograms and Q-Q plots.  There was no difference in the mean PROMIS-
29 scores for individuals using medical products innovated for shorter infusion times (M 
= 12.34, SD = 3.497) and those innovated for longer infusion times (M = 11.46, SD = 
4.162).  Well-being for both groups was not statistically significantly different M = .880, 
95% CI [-.391, 2.150], t (137.542) = 1.369, p = .173. 
The test for homogeneity of variance did not meet the assumption required for 
performing an independent t-test.  Therefore, a Mann-Whitney U test was also conducted.  
Median PROMIS-29 scores for Ability to participate in social roles/ activities did not 
differ significantly for patients with PIDD who used medical products innovated for 
shorter infusion times (Median = 12.00) compared to those who did not (Median = 
12.00), U = 2,486.000, z = -1.619, p = .105.  
 Hypothesis 5 – Infusion Time and HRQOL (Anxiety). The null hypothesis for 




“Anxiety” scores for patients with PIDD who used medical products innovated for 
shorter infusion time versus those who used medical products which were not innovated 
for shorter infusion time.   
A total of 71 individuals were categorized into having shorter infusion times, and 
72 individuals were categorized into having longer infusion times.  A Welch t-test was 
run to determine if there were differences in anxiety between shorter infusion times and 
longer infusion times due to the assumption of homogeneity of variances being violated, 
as assessed by Levene’s test for quality of variances (p = .005).  There were no outliers.  
Data were fairly normally distributed based on skewness and kurtosis values (.227 and -
.637, respectively for shorter infusion times, and -.062 and -1.272, respectively for longer 
infusion times).  There was no difference in the mean PROMIS-29 scores for individuals 
using medical products innovated for shorter infusion times (M = 8.93, SD = 2.885) and 
those innovated for longer infusion times (M = 9.51, SD = 3.650), HRQOL/ Anxiety for 
both groups was not statistically significantly different M = -.584, 95% CI [-1.672, .503], 
t (134.644) = -1.063, p = .290. 
The non-parametric Mann-Whitney U test revealed similarly.  Median PROMIS-
29 scores for Anxiety did not differ significantly for patients with PIDD who used 
medical products innovated for shorter infusion time (Median = 9.00) compared to those 
who did not (Median = 10.00), U = 3,175.000, z = -.914, p = .361. 
Hypothesis 6 – Infusion Time and HRQOL (Depression). The null hypothesis 
for research question 6 was that there would be no difference in mean PROMIS-29 




shorter infusion time versus those who used medical products which were not innovated 
for shorter infusion time. 
A total of 71 individuals were categorized into having shorter infusion times, and 
72 individuals were categorized into having longer infusion times.  A Welch t-test was 
run to determine if there were differences in HRQOL /depression between shorter 
infusion times and longer infusion times due to the assumption of homogeneity of 
variances being violated, as assessed by Levene’s test for quality of variances (p = .001).  
There were no outliers, and the data were relatively normally distributed as determined 
by assessing skewness and kurtosis values (.236 and -1.009, respectively and .430 and -
.775, respectively) between ±1, and histograms and Q-Q plots.  There was no difference 
in the mean PROMIS-29 scores for individuals using medical products innovated for 
shorter infusion times (M = 8.14, SD = 3.030) and those innovated for longer infusion 
times (M = 8.96, SD = 4.143), HRQOL/ Depression for both groups was not statistically 
significantly different M = -.817, 95% CI [-2.017, .382], t (130.082) = -1.348, p = .180. 
According to the non-parametric Mann-Whitney U test, depression did not differ 
for patients with PIDD who used medical products innovated for shorter infusion time 
(Median = 8.00) than for those who did not (Median =8.00), U = 3,119.000, z = .708, p = 
.479. 
Covariates Assessment. I conducted an Analysis of Covariance (ANCOVA) to 
evaluate adjustments to the mean differences of the PROMIS-29 measures across each 
level of medical product innovation by treating age and median annual income as 




PROMIS-29 measures and medical product innovation category for needle sticks and for 
infusion time.  There was homogeneity of regression slopes as evidenced by non-
statistically significant results.  A Shapiro-Wilks test showed that some levels of the 
independent variable (e. g. fewer/ more needle sticks, and shorter/ longer infusion time) 
were non-significant while some were significant.  There was homoscedasticity as 
evidenced through visual inspection of a scatterplot.  The assumption of homogeneity of 
variance, as measured by Levene’s test was not met.  There were no instances of 
standardized residuals greater than ±3 standard deviations.  After adjusting for age and 
for median annual household income, there still was no statistical difference in the mean 
PROMIS-29 scores for individuals using medical products innovated for fewer needle 
sticks or shorter infusion time, and those who were not.    
PROMIS-29 Scores and Switching Therapy. The dataset of individuals who 
had completed the PROMIS-29 survey included those who had reported, including dates, 
one or more changes of medical products.  I ran a two-way independent t-test to 
determine whether there was a significant difference in mean PROMIS-29 scores for 
individuals who reported changing medical products (n = 24) and those who had not (n = 
129).  Inspection of boxplots showed the data had no outliers.  Data were fairly normally 
distributed as evidenced by inspection of Q-Q plots and observation that skewness and 
kurtosis values were between ±1 for each level of independent variable (with the 
exception of the anxiety PROMIS-29 measure for those who changed medical products: 
skewness = -.074, kurtosis = -1.305).  Since those who changed medical products 




results.  The Shapiro-Wilk results were not significant (p = .314 for ability to participate; 
p = .100 for anxiety; and p = .263 for depression).  Levene’s tests for homogeneity of 
variance revealed the assumption of homogeneity was met for the PROMIS-29 HRQOL 
measures, anxiety (p = .875) and depression (p = .327). 
The difference in mean PROMIS-29 HRQOL anxiety scores for individuals who 
changed medical product (M = 9.92, SD = 3.269) and those who did not change medical 
product (M = 9.19, SD = 3.319) was not statistically significant, M = -.723, 95% CI [-
2.177, .732], t (151) = -.982, p = .328. 
The difference in mean PROMIS-29 HRQOL depression scores for individuals 
who changed medical product (M = 9.13, SD = 3.379) and those who did not change 
medical product (M = 8.53, SD = 3.657) was not statistically significant, M = .989, 95% 
CI [-2.178, .998], t (151) = -.734, p = .464. 
For the PROMIS-29 well-being variable, ability to participate in social roles/ 
activities, the assumption of homogeneity of variances was violated as evidenced by 
Levene’s test for equality of variances (p = .037).  Therefore, a Welch t-test was run.  The 
difference in mean PROMIS-29 well-being scores for individuals who changed medical 
product (M =11.04, SD = 4.486) and those who did not change medical product (M = 
12.03, SD = 3.618) was not statistically significant, M = .989, 95% CI [-.994, 2.973], t 
(28.828) = 1.020, p = .316.    
Individuals who switched products and took multiple PROMIS-29 surveys 
The PROMIS-29 survey is offered approximately every six months, and three 




changing medical products from one which had been on the market prior to 2010 to a 
medical product which has been approved between 2010 and present.  Table 7 provides a 
summary of the data.  The maximum raw score in each domain (i.e. ability, anxiety, and 
depression) is 20, and the minimum is four.  For each domain, a higher score means the 
individual reported feeling more of that domain.  Results show that each individual 
reported increased well-being, as measured by the PROMIS-29 ability to participate in 
social roles/ activities from their first to their second survey time point.  Levels of 
HRQOL related to the PROMIS-29 domain for anxiety remained unchanged for Person 
ID 931 and Person ID 2685; and anxiety decreased for Person ID 8121 from their first to 
their second survey time point.  Levels of HRQOL related to the domain for depression 
revealed Person ID 931 unchanged.  However, Person ID 2685 and Person ID 8121 
reported a decrease in depression from their first to their second time taking the 
PROMIS-29 survey.  Overall gains in HRQOL and well-being totaled +1 point for 
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Summary 
In conclusion, individuals using medical products innovated for fewer needle 
sticks or for shorter infusion time had similar mean HRQOL and well-being as measured 
by the PROMIS-29 survey.  The same held true when PROMIS-29 data were evaluated 
according to individuals who had reported switching medical products compared to those 
who had not.  Thus, the null hypothesis of no mean difference between the two groups 
could not be rejected.  Overall, individuals were equally able to participate in social 
activities/ roles.  Overall, individuals were equally likely to be more or less anxious or 
depressed.  Thus, individuals had the same HRQOL and well-being for the medical 
product they were using at the time they took the PROMIS-29 survey.  However, when 




innovated product (e.g. approved 2010 to present) and also took the PROMIS-29 survey 
at approximately the time point of the change, the limited data suggest improvements in 
well-being and HRQOL. 
An assessment of parameters common to all individuals in the patient registry 
demonstrated that those who took the PROMIS-29 survey and those who did not were 
similar in disability distribution.  However, the groups differed in other key aspects such 
as gender, racial, and age distribution.  Furthermore, the groups differed in disease state 
parameters such as age at: symptom onset, diagnosis, and initial use of IGRT.  As a result 
of these differences, it is difficult to generalize the research question findings to the entire 
population of individuals in the patient registry. 
In Chapter 5, I will consider the implications of the findings in context of the 
literature review from Chapter 2 and in terms of potential research areas of the future 




Chapter 5: Discussion, Conclusions, and Recommendations 
Introduction 
In this quantitative dissertation, I evaluated the impact on well-being and HRQOL 
of medical products for PIDD innovated according to patient preferences for fewer needle 
sticks and shorter infusion times by analyzing PROMIS-29 survey scores.  I used the 
PROMIS-29 domain “Ability to Participate in Social Roles/Activities” as a proxy for 
well-being, and the domains of “Anxiety” and “Depression” as proxies for HRQOL.  As I 
noted in Chapter 1, well-being conceptualizes how people thrive in their daily life while 
HRQOL is associated with negative emotions (HealthyPeople.gov, 2017). 
I used t-tests and Mann-Whitney tests to measure whether there were differences 
in the PROMIS-29 scores according to medical product innovation category.  In each 
case, I failed to reject the null hypothesis that there is no mean difference.  In order to 
determine generalizability between the 153 individuals who completed the survey and the 
1,877 individuals in the patient registry who did not take the PROMIS-29 survey, I 
compared common characteristics such as age, gender, race, route of IGRT 
administration, level of disability, age at PIDD symptom onset, age at diagnosis, and age 
at first IRGT use.  Statistical analyses revealed significant differences between the 
populations for all aspects compared, except for level of disability.  Thus, I cannot 
generalize from individuals in the patient registry who took the PROMIS-29 survey to 
those individuals in the patient registry who did not.   
Next, I compared the mean difference in PROMIS-29 scores between individuals 




who reported using a medical product approved prior to 2010.  There was no statistically 
significant difference in PROMIS-29 scores, and I failed to reject the null hypothesis.  
Each group had similar levels of HRQOL and well-being. 
Lastly, three individuals in my dataset reported having changed from a medical 
product innovated prior to 2010 to a medical product innovated in 2010 or later and also 
took the PROMIS-29 survey around the periods of time when they switched.  My data 
suggest that there might be improvements in HRQOL and well-being as measured by 
PROMIS-29 due to the switch to innovative medical product for these individuals. 
Interpretation of the Findings 
The underlying premise of the research questions is that patients have a treatment 
preference for shorter infusion time and fewer needle sticks (Jiang et al., 2015); thus, 
patients taking those medical products would have a higher mean HRQOL and a higher 
mean well-being than patients who did not take these products.  However, the null 
hypothesis that there would be no mean difference could not be rejected.  There might be 
several reasons for this finding, including: (a) perhaps patients were already optimized on 
a therapy regimen of their preference at the time they took the PROMIS-29 survey;  (b) 
statistical power to detect a difference was not present; (c) other factors distributed 
among the groups were more influential; (d) preference for treatment, satisfaction with 
treatment, and HRQOL/well-being, while seemingly similar constructs, might be 
different enough that their measurement involves generating primary data asking specific 




questions; and (e) improvements in HRQOL and well-being are best measured using a 
longitudinal design rather than a cross-sectional design.  
The study findings presented in Chapter 4 are similar to those of other studies.  
For instance, while some researchers have found statistically significant differences or 
changes in HRQOL and well-being, other researchers have found no significant 
differences or changes.  Bienvenu et al (2016) and Espanol et al (2014) both found no 
statistical difference between the route of administration (IV and SC) and quality of life 
as measured by SF-36 and SF-12, respectively.  Other researchers found no difference in 
QOL as measured by SF-12 between treatment bother (e.g., treatment convenience, 
interruptions to life, side effects and reactions, needle sticks, infusion time, number of 
infusions, infusion costs, and operation of infusion delivery medical devices) and route of 
administration (Rider et al., 2017).  
In general, route of administration influences the number of needle sticks and the 
infusion time.  Individuals receiving therapy via subcutaneous injections generally 
receive smaller doses daily to weekly, or biweekly.  Therefore, there is potential for more 
needle sticks but shorter infusion times.  Individuals receiving intravenous injections 
generally receive a large monthly dose and have the potential for fewer injections but 
longer infusion times.   Medical product innovations include making available more 
concentrated formulations (e.g., 5%, 10%, 16%, and 20% formulations exist) so the same 
concentration of therapy can potentially be administered in reduced time and with fewer 
needle sticks.  Other innovations include medical products which allow administration of 




infusion time (Kobrynski, 2012).  However, the proportion of individuals who took the 
PROMIS-29 survey using newer innovative medical products might have been too few to 
detect a difference.  For example, 63 patients were using medical products approved 
since 2010, and only 15 patients were using medical products approved since 2012.   
The findings of this study are supported by literature.  However, mean differences 
in HRQOL and well-being might also have been nonexistent due to patients having 
already been optimized according to the medical products available to them.  For 
instance, data suggested potential improved HRQOL and well-being when the same 
individual took the PROMIS-29 survey around the same time point of changing medical 
products (see Table 7).  Lastly, mean differences might also have been masked by lack of 
statistical power and the small numbers of individuals using the newer innovated medical 
products.   
Some researchers have found that clinical condition (e.g., number and severity of 
infections and comorbidities such as impaired digestive, liver, lung, or neurological 
functioning) is a greater influence on HRQOL than therapy parameters (Rider et al., 
2017; Tabolli et al, 2014).  Rider et al. (2017) found that higher QOL was associated with 
patients having controlled PIDD and limited physical impairment.  Additionally, patients 
who also were not bothered by requirements of treatment (including needle sticks and 
infusion times), and who received infusions at home (whether IGIV or SCIG), had higher 
QOL (Rider et al., 2017).  Rider et al. (2017) found that patients who reported having no 
physical impairment scored higher than the U.S. population for QOL.  The authors found 




population on QOL measures (Rider et al., 2017).  However, these findings align with the 
disability paradox theoretical framework (see Albrecht & Devlieger, 1999; Fellinghauer 
et al., 2012) discussed in Chapters 1 and 2.  
My study findings might be indicative that the ultimate goal of aligning patients 
with medical products catering to their preferences, and thus optimizing their HRQOL 
and well-being has been achieved for this population of individuals with PIDD.  For 
instance, researchers found that patients were satisfied with the therapy they were 
receiving (Bienvenu, 2016).  According to Espanol et al., (2014), satisfaction with 
treatment was related to preferences.  Individuals who preferred one needle stick once a 
month were satisfied if they were receiving IVIG.  Additionally, individuals who were 
satisfied with SCIG preferred self-infusion at home (Espanol et al., 2014).  The 
availability, since 2010, of medical products allowing more choice about when and where 
patients can potentially receive fewer needle sticks and which have a shorter infusion 
time (Ponsford, 2015; Wasserman, 2014) could shift preferences or reasons for patient 
satisfaction as more patients begin using these medications.  In Chapter 1, I mentioned 
the medical product supply chain leading to medical product availability for physicians to 
prescribe.  Espanol et al. (2014) and Seeborg et al. (2015) commented that therapy and 
route of administration are influenced to a large extent by the physician.  These 
researchers urged the need to ensure patient preference considerations in order to 
facilitate better HRQOL and perceived health outcomes.  The balancing act of 
maintaining stable blood serum levels of antibody at the clinical level to stave off chronic 




need demonstrated in the literature.  In this study, I used the biopsychosocial model 
theoretical framework to study psychosocial factors assessed via the PROMIS-29 survey 
on IGRT standard and innovative medical products already proven and approved 
according to clinical outcomes (e.g. stable blood serum levels, fewer infections and 
hospitalizations, leading to fewer missed days of work/ school). 
Limitations of Study 
I used a secondary dataset where the data collected was not specific to my 
research questions.  Regarding needle sticks, some individuals provided information 
about the interval of days between infusions.  This enabled patient-specific placement 
into a category based on their actual use.  For patients who did not report IGRT interval, I 
inferred needle stick information from medical product labeling.  Regarding infusion 
time, there was no available data about infusion time specific to each patient.  Therefore, 
I also inferred this information from medical product labeling.  However, there might 
have been a significant level of variability within my study population within the 
parameters of medical product labeling.  Other limitations included potential confounding 
factors for which data were not available; for example, the length of time patients had 
been receiving their current medical product and/ or therapy, and how successful they 
feel therapy has been.  Limitations associated with PROMIS-29 survey administration 
include those named in Chapter 1 and Chapter 3 regarding selection bias, recall bias, and 





Patient-reported outcomes such as preferences for treatment, satisfaction with 
treatment, and aspects of treatment which lead to increased HRQOL and well-being are 
not necessarily intuitive.  For instance, Elliott & Richardson (2014) noted persons with 
epilepsy preferred not solely a reduction in the number and severity of seizures, they also 
preferred alleviation of the depressive and anxiety manifestations of epilepsy which 
prevented performing functions of life, such as work and school.  Instead of a cure from 
the disease state for patients with rare and common chronic diseases, there is daily 
management and a series of tradeoffs (e.g. medication already in liquid form instead of as 
a lyophilized powder needing to be reconstituted with sterile water; medication which can 
remain at room temperature versus needing refrigeration; medication which can be taken 
less often, or on an empty stomach; or more than one option for route of administration).  
Thus, patient-reported outcomes are a powerful tool for understanding how to make 
outcomes better for patients.  The biopsychosocial model demands a biomedical 
demonstration of medical product performance, and the model demands this clinical 
performance also considers the psychosocial world of the patient. Gathering primary data 
for further study of patient-reported outcomes using the biopsychosocial model 
framework would further the evidence base and scientific discourse for innovative 
medical product development and for regulatory decision-making.    
Implications for Positive Social Change 
This is the first study which used the biopsychosocial model framework to test 




translated to increased HRQOL and well-being when measured by the PROMIS-29 
survey for patients with PIDD.  Research aimed at studying patient psychosocial 
perspectives additional to biomedical perspectives has a potential impact at the individual 
level and at the societal/ policy level because it provides an evidence base for medical 
product development and approval.  Implications for positive social change include 
helping medical product manufacturers and regulatory bodies to verify innovative 
medical products have impact on patient lives beyond solely biomedical parameters and 
clinical endpoints and then to make these products available to patients.  This dissertation 
serves as a guide for how a theoretical framework such as the biopsychosocial model can 
be used along with the PROMIS-29 survey to gain patient feedback and to assess 
innovations made in response to patient feedback for PIDD and other chronic disease 
states.   
I recommend this study be conducted using a longitudinal design where 
individuals about to experience an innovative medical product get a pretest and a posttest 
asking specific questions about their preferences and the medical product innovation, and 
they are provided the PROMIS survey instrument.  Thus, the voice of the patient will 
have an opportunity to be heard with less confounding and with more statistical power to 
form a stronger evidence base.   
Conclusions 
The findings of this study showed that patients with PIDD are generally equal in 
terms of HRQOL and well-being across the variety of IGRT medical products.  Some of 




is valuable to society.  Thus, this study merits repeating using a longitudinal design and 
questions specifically aimed toward linking patient preferences for treatment with the 
PROMIS-29 survey, especially as additional data become available for the more recent 
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Appendix B: USIDNET Query 
I have read the above data use policy and I agree to adhere by its standards.  
  Agree  
Name  
  Niedre Heckman  
Position  
  Doctoral Student - Public Health
Institution  
  Walden University  
Email  
  niedre.heckman@waldenu.edu
I agree to allow the Registry Manager to contact me for follow-up data in the future.  
  
 Agree 
Purpose of Query  
  
 Research for publication
 Improved understanding of diseases (personal knowledge gain) 
What is your overall question (briefly)?
  
What is the change in target audience (patients and caregivers) psychosocial perspectives as a result of 
treatment of PIDD with commercially available biologic therapies delivered through the subcutaneous 
route?  
What study population do you want to capture?
  All PIDD patients; caregivers  
How might the information obtained from the USIDNET registry benefit the primary 
immunodeficiency community? 
  
The information could help the primary immunodeficiency community understand changes (hopefully 
improvements) in quality of life (QOL) parameters resulting from using different therapies. For example, 
patient perspectives can inform drug development and even the regulatory process for drug approval. 
Once the drug is developed and on the market, which of the patient perspectives (specifically related to 
social parameters measured with instruments measuring QOL parameters) shifted as a result of using a 
given drug? Such knowledge could be useful for refining drug development protocol and regulatory 
policy in the future.  
Please list other individuals who will be accessing the requested USIDNET data.  
  I am a doctoral student and I will need to conduct this study independently. I am, however, seeking to collaborate with IDF and was referred to USIDNET through IDF.






 Age of Symptom Onset 












Patient Infections  
  Yes  
Please Select Fields to Include  
  
 ALL Infection Names 
Non-Infectious Conditions  
  Yes  







If you are interested in specific noninfectious conditions, please list in the space below.  
  
records that contain PROMIS-29 QOL data (scores); educational attainment; household income; zip 
code; and 
SF-36; SGRQ; GHQ-12; EQ-5D; or other QOL measures such as those in the CVID_QOL Questionnaire 
(Quinti, I., Pulvirenti, F., Giannantoni, P., Hajjar, J., Canter, D. L., Milito, C. et al. (2016). Development 
and initial validation of a questionnaire to measure health-related quality of life in adults with Common 
Variable Immune Deficiency: The CVID_QoL Questionnaire. J. Allergy Clin Immunol. Pract)  
Allergic Reactions  
  No  




  No  
Ig Therapy  
  Yes  
I would like to include the following fields
  
 Starting Age 
 Route 
 Frequency 
 Adverse Reactions 
 Dose 
Dose Units  
  
 g (total) 
 mg / kg 
If you would like to include additional fields related to Ig therapy, please note accordingly in the 
space below.  
  Name(s) of biologic and drug products used
Anti-Infectives  
  No  
Immunomodulator Therapy  
  No  
Blood Transfusions  
  No  
Surgical Procedures  
  No  
Non-Surgical Treatments  
  No  
Complete Blood Count  
  No  
Lymphocyte Phenotype  
  No  
Memory B Cell Phenotype  
  No  




  No  
Antibody Response  
  No  
Pneumococcal Vaccine  
  No  
TRECs  
  No  
Lymphocyte Function  
  No  
Delayed Hypersensitivity Skin Testing
  No  
Complement Function (CH50)  
  No  
Phagocyte Function  
  No  
Stem Cell Transplants  
  No  
Solid Organ Transplants  
  No  
Gene Therapy  
  No  
Family History  
  Yes  




Genetic Information  
  Yes  
I would like to include the following fields




 Gene Mutation 
Quality of Life Data  
  Yes  
I would like to include the following fields
  
 Alive / Dead 
 Disabilities 
 Days in hospital related to PIDD 
 Lansky/Karnofsky Index 
 
 
